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 1 
INTRODUCTION 
1. The adrenal glands: structure, development and function 
The human adrenal glands are multifunctional endocrine organs producing a 
variety of hormones involved in main physiological processes, like the regulation of 
glucose blood levels, the protein turnover, the maintenance of the hydroelectrolytic 
equilibrium as well as the cardiovascular tone, the tissue response to damages and 
infections, the adaptation to stress conditions. They are paired organs located in the 
retroperitoneum at the upper poles of the kidneys, from which they are separated 
by a weak wall of connective tissue, and directly below the diaphragm, to which 
they are attached by the renal fascia. Both the adrenal glands have an irregular 
pyramidal shape, which becomes semilunar and somewhat larger in the left gland. 
They measure approximately 3 cm in width, 5 cm in length and up to 1 cm in 
thickness, with an overall weight ranging from 7 to 10 grams, although this 
parameters can vary depending on age, sex and physiological conditions. Each 
adrenal gland is enclosed within a capsule of fibroblasts and myofibroblasts, 
surrounded by adipose tissue, and is constituted by two distinct parts, each with a 
unique function: the outer adrenal cortex, representing up to 90% of the entire gland 
and synthesizing glucocorticoids, mineralocorticoids and androgens; and the inner 
medulla, producing catecholamines, adrenalin and noradrenalin, in response to a 
direct sympathetic stimulation. The regulation of the hormone synthesis depends on 
both the gland architecture and the enzymatic pool of single cells, as well as on the 
blood supply. This is assured by a rich network of blood capillaries that, departing 
from the superior, the middle and the inferior suprarenal arteries, penetrate the 
capsule and spread from the external cortex to the central medulla. Thus allows to 
strictly control the delivery of steroid hormones to the blood and therefore to 
regulate the activity of the enzymes involved in their synthesis. Venous blood leaves 
the adrenal glands by the suprarenal veins, usually one for each gland: the right 
suprarenal vein, draining into the inferior vena cava, and the left suprarenal vein, 
draining into the left renal vein (Fig. 1). There are also subcapsular and medullary 
lymphatic plexus that drain to the lumbar and para-aortic lymph nodes (Dobbie & 
Symington, 1966). 
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acetylcholine on the adrenergic receptors. This so called “fight or flight” response, it 
induces many physiological effect requiring energy (such as increased heart rate, 
blood pressure and blood glucose levels, with a general reaction of the sympathetic 
nervous system), which is supplied by substrates derived from glycogen- and 
lipolysis induced by catecholamines themselves in liver, muscle and adipose tissue. 
The first step for catecholamines synthesis is the conversion of tyrosine to L-
dihydroxyphenylalanine (L-DOPA) by the tyrosine hydroxylase, which is regulated 
by a negative noradrenalin feedback. L-DOPA is further decarboxylated to 
dopamine which enters the chromaffin granules, where it is converted to 
noradrenalin by the phenylethanolamine-N-methyltransferase (PNMT). 
Noradrenalin is then released into the cytoplasm by exocytosis and it is converted to 
adrenalin, which enters the granules again, by an ATP-mediated transport, to be 
stored in cells (Fig. 5).Catecholamine secretion is regulated by the sympathetic 
nervous system: the neurotransmitter acetylcholine stimulates the cholinergic 
receptors expressed by chromaffin cells with consequent cell depolarization, 
voltage-dependent Ca2+ channel activation and calcium influx, thus inducing the 
exocytosis of secretory vesicles and the release of their content. Through the blood 
circulation, catecholamines reach their target organs where they are metabolized by 
monoamine oxidases (MAO) and catechol-O-methyltransferases (COMT) (Molina, 
2004).  
Figure5. Schematic representation of the biosynthesis and metabolism of catecholamines. 
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2. Adrenocortical carcinoma 
Primary adrenocortical carcinoma (ACC) is a rare endocrine malignancy 
affecting the adrenal cortex (De Lellis et al, 2004) presenting high heterogeneity and 
aggressiveness, often with an unfavorable outcome. Despite immunohistochemical 
and molecular studies have identified novel biomarkers of diagnostic and 
prognostic relevance, the discrimination between malignant and benign forms 
remains challenging, the molecular mechanism underlying the pathology has still to 
be fully elucidated and the available therapeutic options show limited specificity 
and efficacy. The integration between different methodologies of study may lead to 
a better understanding of the tumor biology and behavior, thus offering the 
potential for classifying the neoplasm and for identifying new therapeutic targets to 
develop a more personalized approach to treat patients. 
 
2.1. Epidemiology 
Among adrenal tumors, that are very common in the general population (4-7% 
incidence) and prevalently diagnosed as nonfunctional adrenal adenomas (ACAs) 
(Young, 2007), adrenocortical carcinoma is quite rare. The estimated incidence is 0.5-
2 per million cases per year in adults, (Kebebew et al, 2006; Golden et al, 2009, 
Fassnacht et al, 2013; Kerkhofs et al, 2013), with a median age of diagnosis in the fifth 
to sixth decades and a female-to-male ratio of 1.5-2.5:1 (Luton et al, 1990; 
Michalkiewicz et al, 2004; Fassnacht & Allolio, 2009). However, a bimodal age 
distribution can be described, as a first peak of occurrence is observed in the first 
decade of life (Wooten & King, 1993; Wasserman et al, 2012). Pediatric ACC shows 
an incidence of 0.2% of all childhood cancers (Miller et al, 1995), with a prevalence in 
children younger than 5 years and older than 10 years (53% and 37%, respectively) 
(Wieneke et al, 2003). A specific population of children in Southern Brazil represents 
an exception, showing an incidence of ACC 10-15 time greater (Michalkiewicz et al, 
2004; Pianovski et al, 2006a) that has been related to the presence of a specific single 
germline mutation in the gene encoding p53 (TP53, p.R337H) (Latronico et al, 2001; 
Ribeiro et al, 2001; Seidinger et al, 2011). 
The majority of adrenocortical carcinomas occurs sporadically, but multiple well-
defined genetic syndromes have been associated with an increased susceptibility to 
Introduction 
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ACC. The most common is Li-Fraumeni syndrome (LFS), a familial disease caused 
by germline mutations of TP53, which associates with an increased susceptibility to 
neoplasms like breast cancer, leukemia, brain tumors and sarcomas (Li &Fraumeni, 
1969). Among these, approximately 3-10% of LFS-associated cancers in children are 
ACC (Wagner et al, 1994; Varley et al, 1999;Rodriguez-Galindo et al, 2005), whilst in 
adults the prevalence of TP53 mutation ranges from 3 to 7% (Herrmann et al, 2012; 
Raymond et al, 2013a). Beckwith-Wiedemann syndrome (BWS) also increases the 
risk for ACC, which can occur, mostly during childhood, in 5-15% of cases 
(Wiedemann, 1983; Lapunzina, 2005). The genetics of this disease bases on the 
alteration of DNA methylation of the 11p15 locus, which harbors the IGF2 and 
CDNKC genes and the nontranslated RNA H19 (Weksberget al, 2005), generally 
leading to the loss of the maternal locus and to the amplification of the paternal one 
(Barlaskar & Hammer, 2007). Multiple endocrine neoplasia type 1 (MEN1) is due to 
inactivating mutations of MEN1 gene and classically associates with 
hyperparathyroidism, neuroendocrine tumors, pituitary adenomas and adrenal 
lesions in 20-55% of cases (Waldmann et al, 2007). Among these, roughly 10% are 
distinct adrenal tumors, with a 1.4% overall rate of ACC (Gatta-Cherifi et al, 2012). 
Alterations in mismatch repair genes and microsatellites instability are hallmarks of 
Lynch syndrome, which increases the risk of malignancies in patient, with an 
occurrence of ACC in 3% of cases (Raymond et al, 2013b). To a less extent, ACC 
associates also with Familial Adenomatous Polyposis (FAP), neurofibromatosis type 
1 and Werner syndrome (Else, 2010). More recently, ACC has been also reported in 
patients with Carney Complex (Anselmo et al, 2012; Morin et al, 2012) and, even if 
very rarely, described in conjunction with congenital adrenal hyperplasia (CAH) 
(Bauman & Bauman, 1982; Barzon et al, 2007). 
 
2.2. Clinical features and presentation 
There are three typical clinical scenarios in which ACC can be discovered in 
adults: approximately 40-60% of cases present the signs and symptoms of hormone 
excess (hypercortisolism, virilization in women, feminization in men) due to the 
presence of functional tumors, which generally associate with a rapidly progressive 
Cushing’s syndrome (Luton et al, 1990;Abiven et al, 2006; Fassnacht & Allolio, 2009; 
Ishikura et al, 2010). The second common clinical presentation is represented by 
Introduction 
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nonspecific symptoms related to the mass growth, such as early satiety, abdominal 
fullness and flank or abdominal pain, when a nonfunctional tumor is present (Luton 
et al, 1990; Fassnacht & Allolio, 2009). In these cases, systemic symptoms can be also 
present (fever, weight loss, anemia, anorexia) and distant metastases can occur, 
principally in lung, liver and bones (Abiven et al, 2006; Libel et al, 2007). Finally, 
roughly 20-30% of ACCs are incidentally discovered during imaging for other 
unrelated medical issues (Fassnacht & Allolio, 2010; Else et al, 2014a). 
ACCs are generally unilateral large tumors, measuring more than 5-6 cm and 
with a weight higher than 100 grams; however, in some cases smaller tumors can 
show malignant features, like loss of homogeneity, presence of foci and irregular 
edges. Grossly, they may appear encapsulated or adherent to or infiltrating the 
surrounding structures, with the cut surface ranging from brown to yellow 
depending on the cell lipid content. Fibrous tissue bundles often separate the tumor 
mass in lobules, hemorrhage and necrosis are commonly present and vascular 
invasion can also be observed. The histological evaluation shows a less ordered 
architecture compared to benign adenomas: compact cells predominate, arranging 
in trabecular and diffuse patterns, and mitotic activity, often with atypical forms, 
can be usually seen. Blood vessel and capsule invasion are commonly observed and, 
together with distant metastases, they define malignancy (McNicol, 2008; Else et al, 
2014) (Fig. 6). 
Figure 6. Gross presentation (A) and histological sections of ACC with the typical observed features: 
an hypercellular population showing tumor necrosis, solid growth pattern, abundant eosinophilic 
cytoplasm and mitotic figures is present (B, C, H) compared to ACA (D). Malignancy is defined by 
direct invasion of the tumor capsule (E) and blood vessels (F, G). Adapted from Else et al, 2014a. 
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Adrenocortical carcinomas typically exhibit a large degree of intratumor 
heterogeneity, as well as different mitotic/proliferative capacity: in fact, numerous 
areas and nodules with different histological phenotypes can be commonly 
observed. Three distinct variants of ACC has been described: the oncocytic variant, 
characterized by large and pleomorphic cells with abundant granular and 
eosinophilic cytoplasm (Erlandson & Reute, 1991; Macchi et al, 1998; Hoang et al, 
2002; Song et al, 2004; Ohtake et al, 2010; Wong et al, 2011); the myxoid variant, 
presenting extracellular deposits of myxoid material (Brown et al, 2000; Suresh et al, 
2005; Karim et al, 2006; Raparia et al, 2008; Papotti et al, 2010; Hsieh et al, 2011; Zhang 
et al, 2011; Sheng et al, 2012); and the sarcomatoid variant, in which spindle cell areas 
or specialized sarcomatous component are present (Coli et al, 2010). 
 
2.3. Diagnosis and classification 
The diagnosis of adrenocortical carcinoma needs investigation of clinical, 
biological and imaging features before surgical intervention and pathological 
examination after tumor removal.  
Since signs and symptoms can vary among patients and part of ACCs are 
incidentally discovered, a preoperative biochemical evaluation, consisting in blood 
and urine measurement of steroid hormones potentially produced by the tumor, is 
suggested for suspected ACC. This allows to establish or exclude the presence of 
hormone excess (glucocorticoids, mineralcorticoids, androgens), to confirm the 
adrenocortical origin of the tumor and to define the malignancy of the lesion 
(particularly in the presence of androgen or estrogen production). Moreover, the 
steroid hormone assessment provides molecular markers for further patient follow-
up and surveillance and can indicate the necessity for post-surgical replacement 
therapy (Else et al, 2014a). Remarkably, urine steroid analysis may represent a new 
potential approach to discriminate ACCs from ACAs since a differential steroid 
precursor and metabolite profile can be observed in malignant versus benign 
tumors (Arlt et al, 2011). In addition, metanephrine urinary and blood level 
assessment can support differential diagnosis from pheochromocyoma. 
Traditional imaging techniques, such as contrast-enhanced computed 
tomography (CT) or Magnetic Resonance Imaging (MRI), are the instrumental 
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11 
choice for initial diagnosis and staging of an adrenal mass basing on tumor size, as 
well as for follow-up, since they allow to detect recurrence and metastasis 
(Bharwani et al, 2011). Functional imaging, performed by Positron Emission 
Tomography(PET) with FDG ([18F]fluorodeoxyglucose) or MTO ([11C]metomidate), 
may also be used to confirm the diagnosis of malignancy or the cortical origin of the 
lesions (Minn et al, 2004; Zettinig et al, 2004). 
The best validating score used as standard for the diagnosis of malignancy in 
adrenal tumors still remains the Weiss system with its modifications (Weiss, 1984; 
Aubert et al, 2002; Lau & Weiss, 2009). It is based on the microscopically evaluation 
of the following nine morphologic items concerning tumor architecture, nucleus and 
invasion: 
− nuclear grade 
− mitotic rate (>5 per 50 high-powered field) 
− atypical mitotic figures 
− eosinophilic tumor cell cytoplasm (>75% of tumor cells) 
− diffuse architecture (>33% of tumor) 
− necrosis 
− venous invasion 
− sinusoidal invasion 
− capsular invasion 
Each item scores 1 when present and the sum of all positives items defines the final 
score. A score ≥ 3 represents the threshold to classify adrenal tumors as ACCs, since 
they often behave in a malignant fashion, with recurrence or metastases in roughly 
80% of cases. Instead,  tumors with a score lower than 2 can be classify as ACAs; 
however the diagnosis of tumors with a score of 2/3remains challenging: in fact, 
sometimes tumors not classified as ACC can develop a malignant behavior (Pohlink 
et al, 2004) and, conversely, some tumors diagnosed as ACC do not behave as 
predicted (Giquel et al, 2001; Lucon et al, 2002). Also, in case of oncocytic or myxoid 
ACC variants the Weiss system results inadequate in defining malignancy (Papotti 
et al, 2010; Duregon et al, 2011; Wong et al, 2011). 
Considering the limitations and criticisms of the Weiss scoring, attemps have 
been made to refine its criteria and to improve diagnosis accuracy (Volante et al, 
2009). Among these, the disruption of reticular network, assessed by reticulin 
histochemical staining, seems to specifically discriminate ACCs from ACAs 
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(Duregon et al, 2013a). In addition, many immunohistochemical methods have been 
developed to improve the differential diagnosis of ACC, mainly focusing on tumor 
cell proliferation and mitotic count. The most widely used is the Ki67 proliferation 
index (Cattoretti et al, 1992;Morimoto et al, 2008). Tumors with a Ki67 ≥ 5% are 
generally considered ACC. Since some ACCs can show a loss of adrenocortical 
differentiation, a battery of immunostains can aid in confirming the adrenocortical 
origin of the tumor, such as α-inhibin (Arola et al, 2000), calretinin (Zhang et al, 
2008), synaptophysin, melanA (MART-1) (Ghorab et al, 2003), SF-1 (Sbiera et al, 2010; 
Duregon et al, 2013b).Furthermore, other molecular markers, like the combined 
expression of the microRNA miR483-3p and Smad4, have been investigated and 
confirmed as potential diagnostic complements to the Weiss score, particularly in 
case of borderline tumors (Wang et al, 2014). 
Tumor size, lymph nodes involvement and the presence of distant metastases are 
the parameters commonly used for adrenocortical carcinoma staging, based on the 
traditional TNM (Tumor, Node, Metastasis) classification system (MacFarlane, 1958; 
Sullivan et al, 1978), modified in 2004 by the World Health Organization (WHO) and 
Union for International Cancer Control (UICC) (De Lellis et al, 2004) and further 
revised by the European Network for the Study of Adrenal Tumors (ENSAT) 
(Fassnacht et al, 2009). This system defines 4 stages for ACC (Tab. 1): tumors strictly 
localized to the adrenal gland are considered as stage I (≤ 5 cm diameter) and II (> 5 
cm diameter); infiltration in the surrounding tissue or involvement of locoregional 
lymph nodes characterize the stage III, whereas stage IV is defined by the presence 
of distant metastases.  
 
 
 
 
 
 
 
 
Table 1. TNM classification systems (UICC/WHO versus  ENSAT modifications)  for ACC staging. 
T1, tumor ≤ 5 cm; T2, tumor > 5 cm; T3, tumor infiltration into surrounding tissue; T4, tumor invasion 
into adjacent organs or venous tumor thrombus (ENSAT classification). N0, negative lymph nodes; N1, 
positive lymph node(s). M0, no distant metastases; M1, presence of distant metastases. 
STAGE UICC/WHO (2004) 
ENSAT 
(2009) 
I T1, N0, M0 T1, N0, M0 
II T2, N0, M0 T2, N0, M0 
III T3, N0, M0 T1-2, N1, M0 
T1-2, N1, M0 
T3-4, N0, M0 
IV 
T1-4, N0-1, M1 
T3-4, N1, M0 
T4, N0, M0 
T1-4, N0-1, M1 
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A recent study from ENSAT suggested to move stage III tumors to stage IV when 
lymphonodes are compromised (Libé et al, 2015); moreover, stage IV has been 
proposed to be further stratified in a, b, c subgroups. In fact, the proposed staging 
combined with grading, R status, age and symptom parameters (GRAS 
classification) have been shown to refine the prognostication of the tumor 
classification (Libé et al, 2015). 
 
2.4. Prognosis and predictive markers 
Despite ACC prognosis is generally unfavorable, with a median survival less 
than 12 months in advanced stage (Sidhu et al, 2004; Kebebew et al, 2006), a marked 
difference among patient exists for disease progression, recurrence and overall 
survival, thus mainly being due to the pathology heterogeneity. In fact, even in case 
of advanced disease, survival can range from few months to several years and an 
exceptional prolonged survival (> 10 years) has been observed in a restricted subset 
of patients with recurrent and metastatic ACC (Hermsen et al, 2008). Age at 
diagnosis, increased cortisol production, as well as the tumor growth rate, correlate 
with a decreased overall survival (Abiven et al, 2006; Assié et al, 2007; Berruti et al, 
2014; Else et al, 2014b). Also, it has been shown that an increased intra-abdominal fat 
associates with worsening survival (Miller et al, 2012). 
The three major criteria to define the disease free survival for localized ACCs and 
the overall survival for metastatic carcinomas are represented by the complete 
surgical resection (R0), the ACC grading (related to the proliferation index) and the 
staging. Tumors completely resected associate with a 5-year survival ranging from 
16 to 55%, whereas this percentage decreases to 5% and the median survival to 12 
months in case of incomplete tumor removal (Schulick& Brennan, 1999; Paton et al, 
2006; Bilimoria et al, 2008; McCauley & Nguyen, 2008; Erdogan et al, 2013). Tumor 
staging is mandatory to assess prognosis, since ACCs with stage I-II  have a better 
outcome than stage III and IV, according to different series (Icard et al, 2001; 
Fassnacht et al, 2009; Lughezzani et al, 2010; Kerkhofs et al, 2013, Libé et al, 
2015).Finally, the proliferation index, such as the percentage of Ki67 and the mitotic 
count, can aid in defining ACC prognosis: in fact, Ki67 has been found to represent 
a single factor predicting recurrence in localized ACCs after R0 resection 
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(Beuschlein et al, 2015) and to be an important prognostic parameter of overall 
survival in stage IV ACCs (Libé et al, 2015); high tumor grade, defined as more than 
20 mitoses per HPF, represents another unfavorable prognostic factor (Miller et al, 
2010; Else et al, 2014b). As reported above, a combination of the new proposed 
staging, grading, R status, age and symptom parameters resulted in a more robust 
prognostication (Libé et al 2015). 
Global gene expression analysis have identified several potential biomarkers that 
could aid in improving diagnosis and prognosis in addition to the classical 
histological parameters. Transcriptome studies (de Reynies et al, 2009; Giordano et 
al, 2009; Laurell et al, 2009; Assié et al, 2010) have described different expression 
profiles discriminating ACCs from ACAs, and identified molecular characteristics 
able to stratify ACC patients into two subgroups, namely clusters C1A and C1B, 
associated with different outcomes: the C1B group presents a marked better 5-year 
survival rate and a transcription signature characterized by the expression of genes 
related to cell metabolism, intracellular transport, apoptosis and differentiation. 
Instead, the poor outcome group C1A generally presents an increased expression of 
transcriptional control and cell cycle-associated genes and high histologic grade, as 
well as TP53 and CTNNB1 mutations (Ragazzon et al, 2010; Ip et al, 2015). Moreover, 
a combination of three genes (BUB1B, PINK1, DLG7) seems to be predictive of 
clinical outcome, identifying subgroups of ACC with different free-disease and 
overall survival regardless to disease stage and grade (de Reyniès et al, 2009; 
Fragoso et al, 2012). DNA methylation and microRNAs expression can also 
discriminate two ACC subgroups with different outcomes, and hypermethylation 
was associated with poor survival (Barreau et al, 2013; Assié et al, 2014). Other 
factors have been reported as associated with poor prognosis in ACC patients, 
including overexpression of pituitary tumor transforming gene 1 (PTTG1) (Demeure 
et al, 2013), low expression of transforming growth factor β signaling mediator 
SMAD and GATA6 (Parviainen et al, 2013) and cyclin E overproduction (Tissier et al, 
2004). 
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2.5. Molecular pathology 
The rarity and heterogeneity of adrenocortical carcinoma are the main 
challenging aspects to be faced in order to elucidate the molecular mechanisms 
underlying the disease evolution, from the onset to the development and 
progression. Once the molecular mechanisms have been elucidated it might be 
possible to develop new specific diagnostic and prognostic tools, as well as to 
improve patient follow-up and treatment. Over recent decades a number of studies 
have identified different biomarkers with diagnostic and prognostic impact by 
employing various approaches. Molecular studies based on the assessment of 
candidate genes led to the elucidation of the genetics of rare syndromes associated 
with adrenocortical tumors, as well as to the identification of the major molecular 
pathways altered in ACC. The recent advent of high-throughput methodologies, 
including genome-wide sequencing, exome sequencing, transcriptome, miRNome 
and methylome, allowed to identify subgroups of tumor characterized by distinct 
and specific genetic markers, molecular pathway activation patterns and clinical 
behavior. Moreover, the dysregulation of signaling pathways involved in 
organogenesis and homeostatic maintenance of the adrenal cortex seems to also 
play a pivotal role in adrenocortical disease. 
 
2.5.1. Genetics 
Adrenocortical tumors show a complex landscape of genetic alterations which 
are cumulative towards malignant transformation. ACCs are particularly 
characterized by a high degree of chromosomal instability, one of the main 
hallmarks of cancer (Hanahan & Weinberg, 2011) which leads to a rapid 
accumulation of somatic mutations (the mutator phenotype phenomenon) (Loeb, 
2011), thus contributing to the disease progression (acceleration of the mutagenesis 
process and acquiring of selective advantage) and the development of resistance to 
therapy. The genetic dissection of ACC, including the identification of genomic 
aberrations, specific gene expression profiles, mutations and epigenetic alterations, 
allowed to define the molecular signature of malignant transformation of 
adrenocortical cells and a better classification of adrenocortical carcinomas. 
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 Chromosomal aberrations 
The first characterization of the gross morphological observation of ACC was 
performed thanks to karyotyping studies, demonstrating the presence of a large 
number of chromosomal aberrations, such as segmental duplications, 
rearrangements and aberrant chromosomes. Further cytogenetic and flow 
cytometry studies corroborated these findings, demonstrating that most ACCs 
exhibit aneuploidy/polyploidy compared to ACAs, which are almost always 
diploid (Klein et al, 1985; Bowlby et al, 1986; Limon et al, 1987; Marks et al, 1992). 
Clonal studies have shown that ACCs are mostly of monoclonal origin, whereas 
ACAs can be both monoclonal and polyclonal (Beuschlein et al, 1994; Gicquel et al, 
1994; Blanes & Diaz-Cano, 2006), thus suggesting the hypothesis of a multistep 
process for adrenocortical tumorigenesis, in which a growth advantage of some 
clones is established: the starting event may be the proliferation of a polyclonal cell 
population triggered by paracrine/endocrine stimuli, with a successive 
accumulation of mutations that are thought to accelerate the neoplastic progression 
of normal cells toward benign lesions and, eventually, to carcinoma (Bernard et al, 
2003; de Fraipont et al, 2005).  
With the advent of the Comparative Genomic Hybridization (CGH) techniques 
these studies were extended to the sub-chromosomal levels, revealing a complex 
pattern of chromosomal aberrations in ACCs compared to ACAs, with multiple 
regions of gains and losses (Kjellman et al, 1996; Zhao et al, 1999; Dohna et al, 2000; 
Sidhu et al, 2002; Gruschwitz et al, 2010; Barreau et al, 2012), that were shown  to 
often harbor oncogenes and oncosuppressor genes, respectively. Chromosomal 
gains were frequently observed at chromosomes 4, 5, 9, 12 and 19, while 
chromosomal losses were most commonly seen at chromosomes 1p, 17p, 22, 2q, 11q. 
The presence of genetic aberrations in ACC were correlated with tumor size 
(Kjellman et al, 1996; Zhao et al, 1999; Sidhu et al, 2002), thus corroborating the 
hypothesis that they may cumulate during the neoplastic progression. Microsatellite 
studies have also allowed to demonstrate that ACCs frequently present allelic losses 
(Loss Of Heterozigosity, LOH) or disequilibrium in the TP5317p13 region (85%), the 
MEN1 11q13 locus (92%) and the Carney Complex 2p16 region (90%) (Kjellman  et 
al, 1996; Gicquel et al, 2001). Some other alterations (amplifications at chromosomes 
6q, 7q and 12q, and losses in chromosomes 3, 8, 10p, 16q and 19q) were associated 
with a decreased overall survival in ACC patients (Stephan et al, 2008). In a more 
Introduction 
17 
recent study, a higher-resolution CGH array was used to assess the diagnostic and 
prognostic value of chromosomal abnormalities in adrenocortical tumors (Barreau et 
al, 2012): alterations were observed more frequently in ACCs (44%) compared with 
ACAs (10%) and chromosomal gains at 5, 7, 12, 16, 19 and 20 and losses at 13 and 22 
were confirmed. Within these regions a group of genes, including fibroblast growth 
factor 4 (FGF4), cyclin-dependent kinase 4 (CDK4) and cyclin E1 (CCNE1), was 
identified to be potentially involved in adrenocortical tumorigenesis. Frequent gains 
at 9q34 region, which includes the Steroidogenic Factor 1 (SF-1), were also found in 
adenomas: the same region was previously shown to be gained in pediatric ACCs 
(Figueiredo et al, 1999; James et al, 1999; Pianovski et al, 2006b). According to  mRNA 
overexpression and strong immunostaining, SF-1 was suggested to be involved in 
adrenal tumorigenesis (Figueiredo et al, 2000; Almeida et al, 2010). Moreover, 
Barreau et al (2012) developed a diagnostic tool to differentiate ACCs from ACAs 
(100% sensitivity, 83% specificity) by using a combination of DNA copy number 
estimates at six loci (5q, 7p, 11p, 13q, 16q, and 22q). Chromosome 1, 5, 7 and 22 were 
further confirmed as discriminating between adenomas and carcinomas (Ronchi et 
al, 2013), while frequent recurrent copy number variations (CNVs) at 5p15 and 
deletions at 22q12.1 have been recently identified (Juhlin et al, 2015). Notably, these 
regions contain TERT and ZNRF3 genes respectively, the latter being the most 
commonly altered gene in ACC (Assié et al, 2014; Juhlin et al, 2015; Zheng et al, 
2016). 
 Gene mutations 
Although adrenocortical carcinoma commonly occurs sporadically, it can manifest 
in the setting of some rare heritable genetic syndromes which have been well 
defined at the level of their genetic basis, contributing to the identification of driver 
gene mutations relevant to the molecular pathogenesis of ACC. 
TP53 and the 17p13 locus. The chromosomal region 17p13 harbors the gene 
encoding the oncosuppressor p53, which mainly acts by halting the cell cycle 
and/or inducing apoptosis and senescence in response to DNA damage or other 
stress stimuli. It represents one of the most frequently mutated gene in human 
cancer (Hollstein et al, 1991; Vogelstein et al, 2000; Suzuki & Matsubara, 2011), with 
both tumor-specific mutations of TP53 gene and alterations of the negative 
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regulators of the p53 protein, thus leading to the final effect of inactivation of the 
oncosuppressor signaling pathway. Germline mutations of TP53 are found in about 
70% of patients with Li-Fraumeni syndrome, which associates with an increased 
susceptibility to ACC. For this reason, the presence of TP53 alterations have been 
investigated in sporadic ACCs. A specific germline mutation in the exon 10 of TP53 
gene (p.R337H) was found in the Southern Brazilian population and it is present in 
up to 90% of ACC patients, with the higher prevalence in children (Latronico et al, 
2001; Ribeiro et al, 2001). While germline TP53 mutations are rare in adult ACC 
patients, somatic mutations have been described in 25-70% of cases (Reincke et al, 
1994; Barzon et al, 2001a; Libè et al, 2007; Waldmann et al, 2012) and LOH at the 
17p13 locus can be described in more than 50% of cases (Gicquel et al, 2001; Soon et 
al, 2008a). According to these findings, TP53 inactivation has been proposed to 
follow the classic Knudson’s two-hit hypothesis for a tumorsuppressor gene, in 
which both alleles are inactivated: in the presence of a germline or somatic TP53 
mutation, a second genetic event, such as a promoter region methylation or LOH, 
determines the inactivation of the second allele. However, since TP53 point 
mutations and 17p13 LOH do not completely overlap, an alternative inactivating 
mechanism has to be involved. More recently the presence of somatic TP53 
inactivation has been demonstrated to represent a molecular signature of ACC and 
to correlate with poor outcome in patients (Ragazzon et al, 2010). Furthermore, also 
the presence of some less common variants of TP53 polymorphisms have been 
associated with a poor outcome in adult ACC patients (Ignaszak-Szczepaniak et al, 
2006; Heinze et al, 2014). The relatively high frequency of TP53 mutations in ACC 
(~15%) has been confirmed in other recent studies investigating the genomic 
landscape of ACC (De Martino et al, 2013; Assié et al, 2014; Ragazzon et al, 2014; 
Juhlin et al, 2015; Zheng et al, 2016), which identified other cell cycle-related genes 
also altered in ACC, including the oncosuppressors CDKN2A and RB1 and the 
oncogenes MDM2 and CDK4. These findings indicate that a global impairment of 
the cell-cycle regulation constitutes a key element in sustaining cancer cell 
proliferation in ACC. 
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 Wnt/β-catenin-related genes. Familial Adenomatous Polyposis (FAP) or 
Gardner's Syndrome, is characterized by the development of multiple colonic 
polyps and is caused by germline inactivating mutations of the APC gene (Nishisho 
et al, 1991; Half et al, 2009). It has been demonstrated that, in many cases, it leads to 
the development of bilateral adrenocortical nodular hyperplasia, general non-
functional and benign, although ACCs have also been described (Marshall et al, 
1967; Marchesa et al, 1997; Kartheuser et al, 1999; Smith et al, 2000; Bläker et al, 2004; 
Gaujoux et al, 2010). APC is a downstream regulator of the Wnt pathway, a network 
of proteins involved in regulating fundamental cell processes during embryogenesis 
and tissue morphogenesis and homeostasis, such as migration, proliferation, 
differentiation, survival, stem cell self-renewal and fate (Moon et al, 2004; Kim et al, 
2013). Wnt signalization is mediated by the interaction between a Wnt ligand and a 
Frizzled family receptor expressed on cell membrane, thus inducing a reaction chain 
which results in the inactivation of the β-catenin destruction complex. This latter is a 
multiprotein complex, constituted by APC protein, axin and GSK3-β enzyme which 
constitutively phosphorilates β-catenin, addressing it toward a proteasome-
mediated degradation. The β-catenin still present in the cytosol localizes at the cell 
membrane, being part of adherent junctions in epithelial tissues. Once the pathway 
is activated,  β-catenin is stabilized and accumulates in the cytoplasm, from which it 
is further translocated to the nucleus, where it acts as a transcriptional factor, 
regulating the expression of target genes (Fig. 8). In Gardner’s syndrome, APC loss 
causes an abnormal constitutional activation of the Wnt pathway, leading to tumor 
development in many organs, including adrenals. A constitutively activated Wnt 
signalization has been frequently observed in many types of cancer (Karim et al, 
2004), associating with cell proliferation, cell motility, epithelial-to-mesenchymal 
transition and resistance to apoptosis (Kim et al, 2013). 
Although in sporadic ACTs somatic APC mutations are rare events (Gaujoux et al, 
2010), CTNNB1 (β-catenin) activating mutations have been found in both ACAs and 
ACCs (Tissier et al, 2005;Gaujoux et al, 2008;Masi et al, 2009) and the up-regulation of 
β-catenin was confirmed by immunohistochemical nuclear staining (Tissier et al, 
2005). CTNNB1isone of the main driver genes in ACC (10-16%), but other factors 
that are part of the Wnt/β-catenin pathway seem to be involved in adrenal 
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controlling gene transcription, also through epigenetic mechanisms (Feng et al, 2017 
in press). Interestingly, other genes involved in histone modification (MLL, MLL2, 
and MLL4) and chromatin remodeling (ATRX, DAXX)has been found altered in 
ACC (Zheng et al, 2016), suggesting a role for epigenetic deregulation in 
adrenocortical carcinogenesis. 
PRKAR1A gene. Protein Kinase cAMP-dependent Type 1 Regulatory Subunit α 
(PRKAR1A) is the main mediator of cAMP signaling (Bossis & Stratakis, 2004) and 
the presence of mutations of its gene is one of the main cause of the Carney 
Complex Syndrome (Kirschner et al, 2000). PRKAR1A has been also demonstrated to 
be involved in endocrine tumorigenesis (Bertherat, 2001) and, particularly, in the 
adrenal tumor development: LOH of 17q22–24, the locus harboring the PRKAR1A 
gene, was found in 23% of ACAs and 53% of ACCs and direct sequencing of 
PRKAR1A gene revealed inactivating mutations in 10% of ACAs, with parallel 
decrease of mRNA and proteins levels (Bertherat et al, 2003). In a more recent study, 
PRKAR1A inactivating mutations were also found in ACCs (11%) (Zheng et al, 
2016), thus expanding the role of PKA signaling in adrenocortical malignancy 
development. 
 Epigenetics 
In the last two decades has been widely demonstrated that the presence of cancer-
specific mutations is not sufficient to exhaustively explain the mechanisms 
underlying tumor development and progression. Epigenetic changes, including 
DNA methylation and microRNA expression dysregulation, are thought to play a 
central role in almost every step of tumorigenesis and tumor evolution, and a 
complex relationship between genetics and epigenetics seems to exists to final 
determine the acquisition of hallmark properties of cancer (Timp & Feinberg, 2013; 
Chatterjee et al, 2017 in press). Particularly for what concerns tumor aggressiveness, 
the dynamism of epigenetics marks appears to better reflect and to potentially 
sustain the phenotypical transitions taking place during cancer cell invasion and 
metastasis. Epigenetic studies of ACC revealed the presence of specific methylation 
and microRNA profiles which allows to better classify the malignancy, with both 
diagnostic and prognostic significance. 
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among 27˙578 CpG sites analyzed, 212 CpG islands in promoter regions of genes 
involved in regulating cell cycle, apoptosis and transcription, were found 
significantly hypermethylated in ACCs compared to ACAs and normal tissues 
(Fonseca et al, 2012). From a third study comes a further confirmation of ACC-
specific hypermethylation in promoter regions, also correlating with prognostic 
features in patients (Barreau et al, 2013). Furthermore, two subgroups of ACC were 
identified: a "CIMP (CpG Island Methylator Phenotype)-high" group, showing high 
methylation levels associated with TP53 inactivation; and a "CIMP-low" group, 
characterized by lower methylation and Wnt signaling activation. These findings 
indicate that different mechanisms are responsible for the transcriptional 
dysregulation and that ACCs with similar phenotype can be heterogeneous 
concerning the molecular mechanisms related to tumorigenesis. More recently, the 
prognostic value of CpG island methylation of some candidate genes has been 
confirmed to be an independent predictor for recurrence and death in ACC, 
together with the classic clinical parameters  (Jouinot et al, 2017). 
MicroRNAs. MicroRNAs (miRNAs) are a class of evolutionary conserved, small 
(18-25 nucleotides) non-coding RNAs that post-transcriptionally regulate gene 
expression by directly targeting mRNAs: they specifically bind the mRNA 3′-UTR 
regions, affecting their stability and translation, or, as recently demonstrated, they 
may target protein coding and 5'-UTR regions (Vasudevan, 2012). After being 
synthesized into the nucleus, miRNAsare exported to the cytosol and act within 
multiproteic effector complexes, the so-called RNA-induced silencing complexes 
(RISCs), which are guided through complementary base pair to their targets (Fabian 
et al, 2010; Czech & Hannon, 2011). Several miRNAs have been identified as 
regulators of genes involved in crucial biological processes, including 
organogenesis, hematopoiesis, cell development, proliferation and invasion, and 
miRNA dysregulation, such as overexpression or deletion, has been associated with 
initiation and development of many types of tumor (Lujambio & Lowe, 2012; 
Markopoulos et al, 2017; Fang et al, 2017): in fact, genomic instability andaberrations 
of mechanisms related to miRNA processing and epigenetic regulation have been 
described as involved in miRNA expression deregulation (Fig. 10) (Calin et al, 2004; 
Lin & Gregory, 2015). Furthermore, miRNA profiling has been shown to be 
potentially used as tumor biomarker easily available, since miRNAs can be directly 
assayed in biological fluids
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the pro-apoptotic proteins BCC3/PUMA, thus protecting cells from apoptosis 
(Veronese et al, 2010). Similar observations were further made also in the human 
adrenocortical carcinoma cell line NCI-H295R (Ozata et al, 2011), confirming the role 
of miR-483-3p as apoptotic regulator. Among the overexpressed miRNAs, high 
miR-210 was also associates with ACC aggressiveness and poor prognosis (Duregon 
et al, 2014) and it results of particular interest since it plays a crucial role in cell 
response to hypoxia (Chan et al, 2012), one of the major cancer hallmark. miR-195 is 
another main deregulated miRNA in ACC, particularly showing down-regulation 
which significantly associates with poor overall survival (Soon et al, 2009). Evidence 
suggests that it promotes apoptosis while inhibits proliferation, as demonstrated 
also in NCI-H295R cells (Ozata et al, 2011). miR-195 has been found down-regulated 
also in childhood ACC together with miR-99a and miR-100, the latter ones having as 
targets several components of the IGF1 signaling pathway (Doghman et al, 2010). A 
specific group of miRNAs belonging to the imprinted DLK1/MEG3 cluster 
(consisting of multiple maternally expressed noncoding RNA genes and paternally 
expressed protein-coding genes) were found down regulated in non-aggressive 
ACC compared to the aggressive ones (Chabre et al, 2013; Assié et al, 2014). 
Deregulated expression of a set of specific miRNAs, including some of the previous 
ones, and their ability to define malignancy have been recently validated (Koperski 
et al, 2017). Other studies have investigated the role of miRNA-processing enzyme 
in ACC tumorigenesis and a significant overexpression of TARBP2, DICER1 and 
DROSHA transcripts has been described in ACC (Caramuta et al, 2013). Another 
regulator of miRNA biogenesis, namely LIN28, has been found underexpressed in 
aggressive ACC compared to their benign counterparts (Faria et al, 2015): this is a 
RNA-binding protein which blocks miRNA processing by Drosha in the nucleus 
and Dicer in the cytosol (Tsialikas & Romer-Seibert, 2015). Finally, miRNAs have 
been evaluated as ACC prognosis markers in different studies assessing the 
circulating miRNA levels in ACC patient blood, either plasma or serum (Chabre et 
al, 2013; Patel et al, 2013; Szabo et al, 2014; Salvianti et al, 2017), and several miRNAs 
differentially expressed in ACC and ACA have been identified: has-miR-483-p5 
levels increase in ACC patients and correlate with tumor stage and prognosis, also 
differentiating non-aggressive from aggressive carcinomas; on the other hand, low 
levels of hsa-miR-195 can discriminate between adenomas and carcinomas, being 
predictive of recurrence risk in ACC patients and confirming the previous data on 
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tumor samples. In addition, some other circulating miRNAs have been described, 
such as the down-regulated hsa-miR‐335 (Chabre et al, 2013) and the overexpressed 
hsa-miR‐100, hsa-miR‐181b, hsa-miR‐184, hsamiR‐210 (Szabo et al, 2014) and hsa-
miR‐34a (Patel et al, 2013). Although the global impact of miRNA deregulation on 
ACC pathogenesis and evolution has to be fully elucidated (Igaz et al, 
2015;Cherradi, 2016) and further validation studies are needed, miRNAs might 
represent promising non-invasive biomarkers for adrenocortical malignancy. 
 Integrated genomic characterization of ACC 
Studying the genomics of adrenocortical tumors at different levels has provided 
several markers able to define a molecular malignancy signature, allowing to better 
discriminate ACC from ACA and to be predictive for patient outcome. Globally, 
they revealed a modulation of gene expression leading to the alteration of pivotal 
signaling pathways regulating cell cycle, chromosomal maintenance, cell survival, 
inflammation, immunity. So far, integrating genomics of ACC allowed to 
discriminate different subgroups that correlate with specific phenotype and 
prognosis (Faillot & Assié, 2016). Moreover, by combining different genomic 
approaches (whole genome sequencing, exome sequencing, SNP array, DNA 
methylation analysis, mRNA expression array, miRNA sequencing), a 
comprehensive "omics"-based ACC classification has been generated in two 
independent international cohorts (Assié et al, 2014; Zheng et al, 2016), which 
concordantly identified two main molecular subgroups of ACC, one counting the 
most aggressive tumors (C1A cluster), and the other defining the most indolent 
forms (C1B cluster), confirming what shown in the previous studies. A third 
molecular subgroup, associating with an intermediate prognosis, could be defined 
between the two. Globally, the two studies confirmed that chromosomal instability 
is the main signature of ACC, with LOH of the IGF2 locus (11p15) as the most 
frequent. The assessment of copy-number alterations and LOH revealed recurrent 
high-level amplifications of TERT, TERF2, CCNE1 and CDK4 and deletions of 
ZNRF3, CDKN2A, RB1. An additional deletion peak was detected at the 
chromosomal locus related to the long noncoding RNA LINC009. Exome and RNA 
sequencing defined the driver events in ACC: both studies identified TP53, CTNNB1 
and MEN1 as the most frequently mutated genes, together with DAXX (Assié et al, 
2014) and PRKAR1A and RPL22 (Zheng et al, 2016). Collectively, gene alterations 
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(mutations, high-amplifications, deletions) result in affecting three major pathways 
in ACC: β-catenin pathway (cell growth and proliferation), p53/Rb signaling (cell 
cycle regulation) and chromatin remodeling (epigenetic regulation). DNA 
methylation profiles were able to well defined the ACC subgroups, particularly 
associating with patient prognosis: the molecular group with the better outcome 
resulted as non-CIMP, while the higher aggressive ACCs presented 
hypermethilation of CpG island in gene promoters (CIMP), with a further 
discrimination between CIMP-high and CIMP-low (Assié et al, 2014; Zheng et al, 
2016). Finally, also miRNA expression profiles were able to discriminate different 
groups of ACC associated with different patient outcome. These results indicate that 
a specific ACC classification might be used to integrate the molecular signature with 
the classical clinical and pathological parameters, thus improving not only the 
diagnosis and prognosis accuracy, but also the global management of ACC patients, 
with the possibility of developing new personalized therapies (Fig. 11). 
Figure 11. Potential ACC re-classification resulting from the integration of the specific molecular 
features with the classical clinical and pathological parameters. Adapted from Armignacco et al, 
2017. 
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2.5.2. Cell signaling pathways: the cross-link between the normal 
homeostatic adrenal maintenance and neoplasia 
Tissue development and homeostatic maintenance are strictly regulated by 
specific factors and molecular mechanisms. This is even more true for the adrenal 
cortex, in which a morphological and functional differentiation has to be maintained 
between the three zones throughout life. The normal adrenal homeostasis is 
mediated by a stem/progenitor cell population which has been demonstrated to be 
located in the peripheral capsular and subcapsular compartment and that is 
responsible for the whole adrenal cortex replenishment, with a centripetally 
displacement of cells toward the cortico-medullary boundary (Vinson, 2003; Kim et 
al, 2009; King et al, 2009; Huang et al, 2010; Wood & Hammer, 2011; Freedman et al, 
2013; Vidal et al, 2016). Notably, the dysregulation of the signaling pathways 
underlying adrenal organogenesis and homeostasis are the same mainly involved in 
adrenocortical disease, including IGF2, Wnt and Protein Kinase A (PKA) pathways, 
as well as telomere protection and maintenance mechanisms, that have been found 
to be implicated in both adrenal function and dysfunction (Penny et al, 2017). 
 IGF2/IGF-1R. As previously described, IGF2 is one of the most common up-
regulated genes in adrenocortical carcinoma, but it is also highly expressed in the 
fetal adrenal (Voutilainen & Miller, 1988; Rainey et al, 2001). IGF2 is part of the IGF 
family of ligands (counting also IGF1) and, together with the IGF receptors (IGF1-R, 
IGF2-R and insulin receptor isoform A, IR-A), the IGF binding proteins (IGFBP 1-6) 
and the IGF binding proteins proteases, constitutes the IGF signaling pathway. The 
interaction between the secreted ligand IGF2 and the IGF-1R activates the 
downstream AKT/PI3K and MAPK signaling to regulate cell metabolism, 
differentiation, proliferation and apoptosis (Kha & Lackner, 2010) (Fig. 12). In 
human adrenal, the IGF pathway mediates ACTH-induced prenatal growth, as well 
as fetal and adult steroidogenesis and homeostatic maintenance (Han et al, 1992; 
l'Allemand et al, 1996; Mesiano & Jaffe, 1997). The main role of IGF2 lies in fetal 
development, and the evidence that IGF2 expression rapidly drops after birth 
(Bolgorosky et al, 2009) suggests a possible mechanisms of fetal/embryonic program 
reactivation in ACC, with the establishment of a paracrine/autocrine mitogenic 
effect of the IGF2/IGF1-R axis, as also observed in ACC cell lines (Logié et al, 1999). 
In association with IGF2, also IGFBP2 results increased in ACC and correlates with 
tumor stage (Boulle
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complex inducing the expression of two specific target genes, DAX1 (Dosage-
sensitive sex reversal, Adrenal hypoplasia congenita critical region on the X 
chromosome, gene 1) and inhibin-α, which are involved in regulating adrenal 
development and adrenocortical cell stem niche maintenance (Parker & Schimmer, 
1997; Parker et al, 2002; Gummow et al, 2003; El-Khairi et al, 2011; Scheys et al, 2011). 
Moreover, SF-1 also interacts with the GATA transcription factors: GATA-4, which 
regulates, in the fetal adrenal, the expression of gene related to steroidogenesis 
(inhibin-α, CYP17, StAR) (Tremblay & Viger, 2003) and that, under LH control, 
drives gonadal differentiation (Looyenga & Hammer, 2006); and GATA-6, which 
induces adrenal differentiation and regulates the expression of steroidogenesis 
enzymes (StAR, CYP11A1, CYP17) in the adult gland (Jimenez et al, 2003; Tremblay 
& Viger, 2003). Deregulation of these factors may play a role in adrenal 
tumorigenesis: in fact, increased GATA-4 mRNA and protein expression have been 
described in both ACAs and ACCs, while GATA-6 seems to be down-regulated, 
mainly in carcinomas (Barbosa et al, 2004; Kiiveri et al, 2004; Kiiveri et al, 2005). 
Indeed, SF-1 seems to play an important role in adrenocortical proliferation 
(Figueiredo et al, 2000; Doghman et al, 2007; Almeida et al, 2010): it has been shown 
an overexpression in pediatric ACCs, also related to frequent gains of its 
chromosomal region 9q34 (Figueiredo et al, 1999; James et al, 1999; Pianovski et al, 
2006b), and SF-1 immunostaining allows to identify cell adrenocortical origin with 
high diagnostic accuracy, as well as high prognostic value (Sbiera et al, 2010; 
Duregon et al, 2013b).  
 As previously illustrated, Wnt/β-catenin is one of the main cell signaling 
pathways altered in ACC, mostly resulting in the up-regulation of the β-catenin 
trascriptional activity. The Wnt pathway presents a complex degree of regulation, 
which includes ligand availability, secretion of different types of frizzled receptor 
inhibitors and autocrine regulation of Wnt ligands. More recently, a key regulation 
system involving the R-spondin-ZNRF3/RNF43 signaling module has been 
described (Fig. 13): ZNRF3 and RNF43 are membrane E3 ligases which negatively 
regulate Wnt by promoting ubiquitination and degradation of Wnt receptors; R-
spondin proteins (RSPO1-4), instead, serve as antagonists of ZNRF3/RNF43, 
suppressing their inhibitory action. In cancer cells, the maintenance of a sustained 
Wnt/β-catenin signaling requires to overcome ZNRF3/RNF43-mediated feedback 
inhibition and mutations of ZNRF3
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WNT-induced carcinogenesis, whereas a decrease in PKA activity associates with 
higher levels of WNT-related gene expression, thus favoring the acquisition of 
malignant features (Drelon et al, 2016). 
Other growth factors. The Fibroblast Growth Factors (FGFs) constitute another 
family of ligands commonly involved in development, homeostasis and repair 
processes, as well as in cancer (Carter et al, 2015). They can activate several different 
pathways depending on cell context, including Ras/MAPK (cell proliferation and 
differentiation), PI3K/AKT (anti-apoptotic signaling) and PKC (cell migration) 
(Turner & Grose, 2010). Studies in mice revealed that FGF signaling is essential for 
both fetal adrenal development and adult gland growth (Guasti et al, 2013) and it 
has been proposed that their signalization may be implicated in ACC biology, since 
some expression profile analysis have identified an enrichment of FGFR1 and 
FGFR4 receptors in ACCs compared to ACAs (de Fraipont et al, 2005; Laurell et al, 
2009; Brito et al, 2012). Indeed, b-FGF2 seems to be the best candidate to be 
evaluated in adrenocortical tumors, as it is highly expressed in adrenal tissue and it 
has been showed to have a powerful mitogenic action in fetal and adult adrenal cell 
cultures (Mesiano et al, 1991; Feige et al, 1998), as well as in the adrenocortical cell 
line NCI-H295R (Boulle et al, 2000). 
The Transforming Growth Factor-β1(TGF- β1) is another modulator of cell growth 
involved in the regulation of fetal and adult adrenal. A decreased expression of its 
mRNA has been observed in ACC, whereas it is not true for its receptor (Bocuzzi et 
al, 1999; Arnaldi et al, 2000). 
The Epidermal Growth Factor Receptor (EGFR) is a tyrosine kinase-coupled 
receptor which mediates a signalization involved in the regulation of cell fate, 
proliferation, survival, cell cycle control, differentiation and motility through the 
Ras/Raf/Mek/Erk pathway (Shields et al, 2000). Immunohistochemistry studies 
have shown that EGFR overexpression is almost ubiquitous in ACCs (Kamio et al, 
1990; Edgren et al, 1997; Adam et al, 2010), even if frequency of somatic activating 
mutations is low. Recently, it has been shown that co-inhibiting EGFR and IGF-1R 
signaling significantly decrease cell proliferation and viability (Xu et al, 2016). 
Telomeres, TERT and TERF2 expression. The adrenal gland acquires its final 
structure and function thanks to a remodeling process of the fetal zone soon after 
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birth and throughout childhood, in which a balance between proliferation, 
apoptosis and differentiation is established in order to reach the steroidogenic cell 
number sufficient to sustain the global function of the gland. Normal cells can 
replicate within a limited number of division, after that they enter a quiescent phase, 
the so-called "replicative senescence". This phenomenon is due to the telomere 
shortening at the chromosome ends: their function of stabilizing chromosomes and 
protecting their ends from nuclease activity and DNA damage response (de Lange, 
2004; Verdun & Karlseder, 2007) is progressively lost, driving cells toward 
quiescence. However, cells with a high proliferative rate, such as stem/progenitor 
cells, germ cells or neoplastic cells, can avert telomeres shortening by activating the 
enzyme telomerase. This is a ribonucleoprotein complex consisting of a protein 
component TERT (Telomerase Reverse Transcriptase), with reverse transcriptase 
activity, and a ribonucleotide subunit TERC (Telomerase RNA Component), which 
serves as a template for telomere elongation, catalyzing the extension in the 5'→3' 
direction (Bekaert et al, 2004; Cohen et al, 2007; Shay, 2016). Telomerase and telomere 
maintenance play a pivotal role in adrenal homeostasis, with increased telomerase 
expression and telomere length in populations supposed to be part of the adrenal 
stem niche (Else, 2009). Instead, normal adult adrenal cells lose telomerase activity 
and telomeres shorten every division, thus inducing a decline of the cell replicative 
potential (Yang et al, 2001). Nevertheless, it has been demonstrated that restoring 
telemerase activity by transfecting cells with the hTERT subunit prevents telomeres 
from shortening and induces a rapid cell proliferation; contrarily, when neoplastic 
cells are deprived from telomerase, they progressively lose their malignant 
properties (Sun et al, 2004). Notably, the investigation of the telomere length 
maintenance mechanism (TMM) in adrenal tumors demonstrated that malignant 
tissues present at least one TMM compared to benign tumors and normal adrenal, 
as also confirmed in adrenocortical cell lines (Else et al, 2008). Moreover, it has been 
shown that ACCs have a significantly higher telomerase activity compared to ACAs 
and it correlates with tumor dimension (Mannelli et al, 2000). The role of telomeres 
in the etiology of adrenocortical neoplasia is even more supported by the recent 
ACC genomic characterization (Assié et al, 2014; Pinto et al, 2015; Zheng et al, 2016): 
TERT has been identified as one of the candidate driver genes showing frequent 
high-level amplifications, together with current focal amplifications of TERF2 
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(Telomeric Repeat Binding Factor 2), thus indicating that this key stem cell pathway 
is strongly involved in promoting cancer cell survival. 
 
2.6. Therapeutic approaches 
Despite the recent advances in the understanding of ACC molecular 
pathophysiology, as well as in multimodality treatment, the curative options for this 
malignancy still remain limited to the complete surgical resection, aided by 
adjuvant therapies aimed to decrease the chance of recurrence. In case of 
unresectable or metastatic ACC, when tumor aggressive behavior frequently 
associates with an extremely poor prognosis, all therapy is considered as a palliative 
to improve patient quality of life and minimize side effects related to antineoplastic 
therapies. However, the assessment of ACC genomic landscape could provide new 
insights into the genetic and biologic heterogeneity of the tumor, thus allowing to 
identify a set of new potential therapeutic targets exploitable for the development of 
more specific and effective drugs.  
 
2.6.1. Surgery 
Complete surgical resection (R0) is the treatment of choice for localized ACCs, 
with particular attention to preserve the tumor capsule intact in order to avoid 
cancer cells dissemination. Preoperative evaluation, including biochemical 
evaluation and imaging, and operative planning are pivotal to assure the best 
outcome. The optimal surgical approach needs considerations about tumor 
dimension and secretion, lymph nodes involvement and invasion of adjacent 
organs, depending on the single case (Else, 2014).  Open adrenalectomy (OA) with 
lymph node dissection is regarded as the standard treatment for ACC (Bellantone et 
al, 2015), especially in case of infiltrating tumor or suspected lymph nodes. 
Laparoscopic adrenalectomy (LA) may also be performed in case of stage I-II ACCs 
with a diameter < 8-10 cm, even if the choice between OA and LA remains 
controversial considering the data obtained from retrospective series investigating 
surgery efficacy and safety (Gonzalez et al, 2005; Brix et al, 2010; Leboulleux et al, 
2010; Miller et al, 2010; Porpiglia et al, 2010). However, it has to be considered that, 
despite also in patients with metastatic disease surgery seems to improve survival 
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(Livhits et al, 2014), even after complete resection the recurrence rate remains 
between 19 and 34% basing on tumor stage, often with metastases occurring 
(Bellantone et al, 1997; Schulick & Brennan, 1999; Icard et al, 2001). 
 
2.6.2. Mitotane adjuvant treatment 
Due to the high rate of local recurrence, surgery is routinely followed by 
adjuvant treatment with the adrenolytic drug mitotane [1-(o-chlorophenyl)-1-(p-
chlorophenyl)-2,2-dichloroethane, o,p'-DDD]: this is a synthetic derivative of the 
insecticide DDT (dichlorodiphenyltrichloroethane) and it is the only drug approved 
by the U.S. Food and Drug Administration and European Medicine Executive 
Agency for the treatment of adrenocortical carcinoma (Schteingart et al, 2005). 
Mitotane shows a relative specificity for the zona fasciculata and reticularis of the 
adrenal cortex, where it exerts its cytotoxic function following the metabolization 
into the metabolites 1,1-(o,pdichlorodiphenyl)-2,2dichloroethene (o,p′DDE) and 1,1-
(o,pdichlorodiphenyl)acetic acid (o,p′DDA) (Martz &  Straw,1980; Cai et al, 1995a, 
1995b). Active mitotane metabolites inhibit the adrenocortical steroidogenic 
pathways, mainly targeting enzymes involved in cortisol metabolism, such as StAR 
and the cholesterol side-chain cleavage enzymes CYP11A1 and CYP11B1 (Cai et al, 
1997; Lindhe et al, 2002; Lin et al, 2012). In cells, mitotane is able to decrease cell 
proliferation and cortisol secretion (Lindhe & Skoseid, 2010) and it is thought to act 
primarily by affecting the mitochondrial function, altering mitochondrial 
respiratory chain activity and thereby inducing an apoptotic process (Sinsheimer & 
Freeman, 1987; Hescot et al, 2013; Poli et al, 2013). The endoplasmic reticulum has 
been recently identified as another key target of mitotane (Sbiera et al, 2015). 
However, the exact pharmacological mechanism of its antitumor action remains to 
be fully elucidated, despite it has been also investigated by microarray and 
proteomic techniques (Stigliano et al, 2008; Zsippai et al, 2012; Lehmann et al, 
2013).Some studies have identified a functional relation between the expression of 
the RRM1 (Ribonucleotide Reductase Large Subunit 1) gene and mitotane 
sensitivity in adrenocortical carcinoma cell lines (Volante et al, 2012; Germano et al, 
2015), hypothesizing that RRM1 may interfere with mitotane metabolism. However, 
this mechanism still remains to be clarified. 
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Mitotane adjuvant treatment administered soon after surgery has been shown to 
significantly improve the median tumor-free survival in patients with completely 
resected ACC (Terzolo et al, 2007; Terzolo et al, 2012; Fassnacht et al, 2013). However 
some evidence indicates that only a subgroup of patients may benefit, probably the 
one with cortisol-producing tumors (Bertherat et al, 2007). Contrarily, the efficacy of 
mitotane in case of not completely resected, metastasized or recurrent ACC is well 
established and mitotane response, measured as stable disease or partial remission 
after the treatment, is observed in only 25-30% of patients (Else, 2014).The major 
factor influencing the therapy response is represented by the target plasma 
concentration of mitotane, ranging from 14 to 20 mg/l: several studies showed that 
patients with advanced ACC who reached mitotane plasma levels higher than 14 
mg/l have less recurrence and a prolonged recurrence-free and overall survival 
(Terzolo & Berruti, 2008; Hermsen et al, 2011; Terzolo et al, 2013). Thus, monitoring 
mitotane plasma concentration is of great importance for the therapy management. 
However, mitotane doses usually used to reach the therapeutic window often 
associates with a range of significant toxicity, which commonly leads to 
gastrointestinal, neurological, metabolic and endocrine adverse effects (Else, 2014), 
thus inducing drug withdrawal in some cases. For advanced ACC, multiple 
combination regimen have been investigated, particularly the EDP (Etoposide, 
Doxorubicine, Cisplatin) plus mitotane (Berruti et al, 1998) and the Streptozotocin 
plus mitotane (Khan et al, 2000), the first one currently being the standard treatment 
option (FIRM-ACT phase III trial, Fassnacht et al, 2012). However, the improvement 
of disease control with polychemotherapy remains quite modest and 
chemoresistance often develops. Notably, mitotane has been shown to strongly 
induce P450-34A (CYP34A) (Kroiss et al, 2011; Chortis et al, 2013), a drug-
metabolizing microsomal enzyme expressed in liver and gut: this may lead to 
significant drug interaction, decreasing the efficacy of combination strategies and 
partially explaining the development of chemoresistance. 
 
2.6.3. Radiotherapy 
Historically, ACC was considered resistant to radiotherapy and the use of this 
treatment remains controversial considering efficacy versus side effects related to 
the normal tissue toxicity in proximal radiosensitive structures, such as kidneys, 
Introduction 
39 
stomach, intestine and spinal cord (Milgrom & Goodman, 2012). However, 
advances in radiotherapy techniques, particularly the possibility to modulate the 
radiation intensity, have made the treatment safer and promising results have been 
obtained in ACC patients in both adjuvant and palliative settings (Fassnacht et al, 
2006; Hermsen et al, 2010; Sabolch et al, 2011, 2015; Habra et al, 2013). Studies in vitro 
suggest a possible synergistic inhibition of cell growth by the combination of 
irradiation and mitotane administration (Cerquetti et al, 2008). Nevertheless, the 
radiotherapy efficacy still needs to be firmly established. 
 
2.6.4. Targeted therapy 
The limited effectiveness of the traditional available therapies for ACC has led to 
explore new modes of treatment, starting from the molecular alterations described 
for this malignancy to be exploited as pharmacological targets (Costa et al, 2016). 
Tyrosine-Kinase (TK) receptors and their downstream effectors mediating the main 
signaling pathways altered in ACC were the most promising molecular targets (Fig. 
15), and many studies have been performed to investigate the efficacy of different 
inhibitors. The most data concern the IGF-1R antagonists: among all, linsitinib (OSI-
906), a small molecule inhibitor of both IGF-1 and insulin receptor, generated great 
expectation basing on early clinical results (Barlaskar et al, 2009). Despite it reached 
a phase III trial, it has been prematurely stopped since it did not show any 
improvement of overall survival compared to placebo (Fassnacht et al, 2015). A 
possible explanation may be the previous exposure of most of the enrolled patients 
to mitotane, thus activating CYP3A4 and affecting linsitinib efficacy. Also, IGF-1R 
may not be a major driver in adrenocortical carcinoma and other compensatory 
growth-promoting pathways can activate. All the other previous trials with IGF-1R 
inhibitors, including the antibodies Figitumumab and Cixutumumab, were 
precociously stopped due to the lack of response (Haluska et al, 2010; Naing et al, 
2011). However, the IGF-2 pathway remains of great interest since one of its 
downstream components, the mammalian target of rapamycin (mTOR), has been 
shown to be a potential therapeutic target in ACC (Doghman et al, 2010; De Martino 
et al, 2014). Particularly, targeting mTOR together with other effectors of 
proliferation signaling seems to be the best way to avoid the activation of 
compensatory growth pathways (De Martino et al, 2012; Doghman & Lalli, 2012; 
 Naing et al, 2013). Other TK inhibitors have been tested 
growth signal trasduction
signaling (Quinkler et al
disappointing results. Likely, this is due
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Imatinib, a platelet-derived growth factor receptor (PDGFR) inhibitor, 
inducing response in ACC patients (Gross 
been achieved in metastatic patients by using a combined therapy (Halperin
2014). As already described
worse outcome in ACC patients. A phase II study has shown a partial response of 
patients with metastatic or non resectable ACC to the FGFR TK inhibitor dovitinib 
(Jesùs Garcia-Donas
sustained angiogenesis and targeting Vascular Endothelial Growth Factor (VEGF) 
and its receptor generated encoura
VEGF and VEGFR was shown to be increased in ACC
Zacharieva et al, 2004; Xu 
Figure 15. TK receptors abnormally activated in ACC and their downstream effectors addressed for 
targeted therapy with specific compounds in preclinical studies and clinical trials. Adapted from 
Lerario et al, 2014. 
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sorafenib, sunitinib and bevacizumab, have been tested in ACC but, again, with no 
meaningful clinical benefits (Wilhelm et al, 2004; Wortmann et al, 2010; Berruti et al, 
2012; Kroiss et al, 2012; O'Sullivan et al, 2014). More recently, the TK receptor c-Met, 
activated by the Hepatocyte Growth Factor (HGF), has been shown to associate with 
ACC growth and chemoresistance development; moreover, pharmacologically 
targeting this pathway, such as with the use of cabozantinib, an inhibitor of both 
VEGFR and c-Met, allows to significantly suppress cell proliferation and tumor 
growth (Phan et al, 2015). 
Steroidogenesis represents another target of interest in the development of new 
therapies for ACC. The nuclear transcription factor SF-1, which plays a critical role 
in adrenal development and growth, has been shown to induce both proliferation in 
adrenocortical carcinoma cells and tumor growth in vivo (Doghman et al, 2007); on 
the other hand, SF-1 inverse agonists are able to inhibit proliferation in SF-1 
expressing cells (Doghman et al, 2009). Such results, together with evidence of SF-1 
overexpression in ACC tumor samples (Sbiera et al, 2010) and the identification of 
new SF-1-related genes (Mizutani et al, 2015), indicate the potential use of this factor 
as a novel therapeutic target. Another target involved in steroid biosynthesis is 
represented by the Acetyl-CoA acetyltransferase 1 (ACAT1), the enzyme catalyzing 
cholesterol ester formation: a phase I trial (NCT01898715) is currently ongoing to 
investigate a ACAT1 inhibitor (ATR-101-001) in patients with advanced ACC (Aung 
et al, 2015). Intracellular cholesterol availability is crucial for steroidogenesis, so 
disrupting cholesterol uptake could have therapeutic potential in ACC. A promising 
approach seems to be the use of synthetic high-density lipoprotein (HDL) 
nanoparticles inhibiting cholesterol transporters (Subramanian et al, 2016). 
Basing on recent advances in unraveling ACC molecular pathophysiology, new 
potential pharmaceutical target are coming out: Wnt/β-catenin pathway is one of 
the best candidates, and pre-clinical data support the use of anti-Wnt monoclonal 
antibody in many types of cancer (He et al, 2004). So far, no clinical trials with Wnt 
inhibitors have been performed yet, but there is evidence that the small-molecule 
inhibitor PKF115-584 decreases proliferation in ACC cells in vitro (Doghman et al, 
2008) and that silencing β-catenin results in cell proliferation decrease, cell cycle 
alteration and apoptosis induction (Gaujoux et al, 2013). Another strategy could be 
targeting the immune system: interleukin-13 receptor alpha2 (IL-13Ra2) has been 
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found overexpressed in ACC compared to ACAs and normal adrenals (Jain et al, 
2012) and a phase I study has been recently conducted with systemic interleukin-13-
Pseudomonas exotoxin in metastatic ACC patients, with 1 patient out of 5 reaching 
a stable disease for more than 5 months before progression. (Liu-Chittenden et al, 
2015). Other three clinical trials are currently enrolling patients to investigate the 
immunotherapy inhibition of lymphocyte programmed cell death protein 1 (PD-1) 
in adrenocortical carcinoma (NCT02673333, NCT02720484 and NCT02720484). 
 A reliable approach to identify new therapeutic compounds to treat ACC may be 
the use of drugs already approved for other diseases, mainly those demonstrated to 
also exert an anti-neoplastic effect. Among all, some pharmacological classes of 
antidiabetics, such as thiazolidinediones (TZDs) and metformin, have been widely 
investigated for their potential effect on solid tumors, for both cancer prevention 
and therapy (Tuccori et al, 2017), and different studies have described some 
effectiveness also in ACC.  
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor-gamma 
(PPARγ) agonists approved for the treatment of metabolic syndrome and type 2 
diabetes, since they are able to improve insulin sensitivity, as well as to regulate 
adipocyte differentiation and fat redistribution (Myazaki et al, 2002). In addition, 
TZDs have been shown to exert anti-cancer effects and accumulating evidence 
suggests a parallel PPARγ-independent action, with a selective inhibition of IGF-1R 
signaling (Mughal et al, 2017). TZDs, particularly Rosiglitazone and Pioglitazone, 
seem to be effective also in ACC, since they are able to decrease adrenocortical 
cancer proliferation and invasiveness, as well as to induce cell differentiation and 
apoptosis (Betz et al, 2005; Ferruzzi et al, 2005; Cantini et al, 2008; Luconi et al, 2010; 
Cerquetti et al, 2011). Moreover, they seem to affect steroidogenesis by inhibiting 
CYP11B2 enzyme expression and aldosterone production (Uruno et al, 2011). 
However, the exact molecular mechanism still needs to be fully elucidated. 
Metformin is the first-line therapy in the treatment of type 2 diabetes mellitus, 
acting as insulin-sensitizer and glucose-lowering. In addition, it has been 
demonstrated to reduce tumor incidence in diabetic patients (Evans et al, 2005; 
Decensi et al, 2010; Monami et al, 2011; Johnson & Bowker, 2011) and ongoing 
clinical trials are currently testing metformin efficacy in cancer prevention and 
therapy (Pollak, 2013; Quinn et al, 2013; https://clinicaltrials.gov). Poli et al. 
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investigated the role of metformin in ACC treatment, showing a significant effect in 
reducing cell proliferation both in vitro and in vivo, mediated by metformin 
inhibition of the IGF2/IGF-1R signaling and a concomitant activation of the intrinsic 
apoptosis pathway (Poli et al, 2016). The global effect likely impairs mitochondria 
and cancer cell metabolism, as also confirmed in a more recent study analyzing the 
transcriptome and metabolome of ACC H295R cells treated with metformin 
(Udhane et al, 2017). Furthermore, the anti-cancer effect of metformin has been 
proven in a clinical case of metastatic and chemoresistent ACC (Brown et al, 2017), 
thus providing new evidence for using this drug as a potential therapeutic adjuvant 
in adrenocortical carcinoma treatment. 
The identification of novel biomarkers would help in developing more effective 
therapeutic strategies for adrenocortical carcinoma. Few studies have analyzed the 
proteomic profile of ACC (Yang et al, 2013; Kjellin et al, 2014; Poli et al, 2015), 
identifying protein patterns differentially expressed in ACC compared to ACA and 
normal adrenal tissues. Calreticulin, a Ca2+ binding protein involved in processes 
such as cell adhesion, autoimmunity and heat shock, has been identified as 
overexpressed in ACC compared to ACA and shows significant correlation with 
tumor stage (Yang et al, 2013). Other proteins identified as differentially expressed 
in ACC mostly associate with mitochondrial function and glucose metabolism 
(Kjellin et al, 2014; Poli et al, 2015), suggesting that a shift toward aerobic glycolysis 
occurs also in adrenocortical carcinoma and tahat mithocondria play a crucial role in 
adrenal tumorigenesis. Moreover, also proteins involved in cytoskeletal 
organization and cell migration, such as adenylyl cyclase-associated protein 1 (CAP-
1) and Fascin-1 have been found overexpressed in ACC (Poli et al, 2015). Taken 
together, these findings could drive the development of novel specific ACC 
therapies. 
 
2.7. Experimental models of ACC 
Developing new specific and effective treatment for adrenocortical carcinoma 
still remains challenging, not only for the lack of well-defined molecular targets, but 
also because just few cell lines are currently available and very often novel 
therapeutic strategies showing promising results in vitro fail when translated into 
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the clinics. This is due to the patient heterogeneity and the specific therapeutic 
response of individual tumors on one hand, and to the acquisition of genomic and 
phenotypic alterations during long-term cell culture expansion on the other, thus 
resulting in a significant variability between different laboratories, particularly 
when these same cells are used to generate xenograft models (Hantel et al, 2016). 
However, getting proper preclinical models is crucial for the screening of new 
drugs.  
One of the first established cell model of ACC is represented by the SW-13 
adrenocortical cell, that were derived from a small cell carcinoma in the adrenal 
cortex (Leibovitz et al, 1973). Nevertheless, they do not show any steroid production 
and the adrenocortical origin of the primary tumor has been repeatedly questioned. 
 The most widely used human ACC cell line is the NCI-H295R: it has been 
established from an invasive primary adrenocortical carcinoma and further 
characterized for adrenal steroid production and tumorigenicity in nude mice 
(Gazdar et al, 1990; Logié et al, 2000), showing the ability to reproduce the 
morphological features of the original patient tumor. NCI-H295R xenografts 
provided a good model for the dysregulated IGF2/IGF1R pathway typically 
observed in ACC (Barlaskar et al, 2009; Hantel et al, 2012). They have been also used 
after β-catenin inactivation using a doxycyclin (Dox) inducible shRNA plasmid to 
study in vivo the role of Wnt/ β-catenin signaling in adrenocortical tumorigenesis 
and progression (Gaujoux et al, 2013), as well as for preclinical evaluation of therapy 
regimens (Doghman & Lalli, 2013; Hantel et al, 2014) and for the development of 
new therapeutic strategies (Gaujoux et al, 2013; Hantel et al, 2012; Szabó et al, 2014). 
More recently, a mouse xenograft model of metastatic adrenocortical carcinoma has 
been established: SF-1-inducible H295R cells tagged with both firefly luciferase and 
GFP were generated to perform intrasplenic injection in mice followed by 
splenectomy, thus inducing metastases traceable by chemoluminescence (Morin et 
al, 2017). 
The selection taking place during the multiple in vitro passages grossly changes 
the cancer cell biological properties. Thereby, the research in this field is now 
focusing on the development of patient-derived tumor xenograft (PDTXs), that 
could allow to reproduce the patient's specific tumor features, actually reflecting 
ACC heterogeneity (Hantel et al, 2016). Accordingly, a model of adult ACC (both 
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xenograft and cell line) has been recently obtained from a PDTX referred as MUC-1 
(Hantel et al, 2016). Also, a pediatric tumor model of ACC (SJ-ACC3) has been 
established by implanting the tumor tissue of a 11-years old patient into immuno-
incompetent mice, eventually obtaining a reproducible xenograft model showing 
the patho-morphological features of the original patient tumor (Pinto et al, 2013).  
Interestingly, a transgenic mouse model of metastatic adrenocortical cancer has 
been recently generated through the specific adrenocortical expression of SV40 large 
T-antigen, which selectively inactivates p53 in the adrenocortex, thus resulting in a 
spontaneous development of metastatic adrenal tumor after 8 months (Batisse-
Leigner et al, 2017). 
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3. Beyond the tumor mass: the role of tumor microenvironment 
in sustaining tumor progression 
A growing tumor mass can be considered as a dynamic "pseudoorgan" consisting 
of heterogeneous cancer and stromal cell populations, among which an active 
molecular and metabolic interaction is continuously established, thus contributing 
to favor the adaptation of cancer cells to different challenging conditions linked to 
tumor growth, such as physical pressure, oxidative stress, changes in nutrient and 
oxygen availability, immune surveillance. The features and behavior of the tumor 
surrounding environment significantly contribute to disease progression, allowing 
cancer cells for reprogramming their metabolism, dynamically adapting to a 
variable and somewhat hostile microenvironment and eventually acquiring the 
ability to successfully metastasize to distant sites. This is a complex process that 
primarily depends on tumor heterogeneity, which is due on both unique 
combinations of genetic and epigenetics alterations within the tumor cell 
populations, and on the ability of cancer cells to engage different metabolic 
strategies to overcome different tricky environmental conditions. These alterations 
allow cancer cells to acquire self-sufficiency in growth signals and a limitless 
replicative potential on one hand, and to become resistant to antigrowth signals and 
to programmed cell death on the other one, meanwhile developing the ability to 
induce angiogenesis and eventually invade the surrounding tissues to further 
metastasize. The so called "oncometabolism" has now entered among the defining 
hallmarks of cancer (Hanahan & Weinberg, 2011; Fouad & Aanei, 2017): tumor cell 
metabolic flexibility underlies the balance between energy-producing and energy-
consuming processes to manage the need for essential nutrients (Pavlova & 
Thompson, 2016). Glucose represents a key fuel source and its uptake is usually 
increased in cancer cells: it is preferentially metabolized through glycolysis, that can 
be both anaerobic, when the molecular oxygen is limiting (for example, in the core 
of hypoxic areas of the tumor mass distant from the peripheral blood vessels) and 
aerobic, during the establishment of the "Warburg effect" (Warburg et al, 1927), 
which allows to rapidly produce ATP and to divert the glycolytic intermediates into 
various biosynthetic pathways, thus sustaining cell proliferation. Glutamine 
metabolism also supplies essential substrates for cancer growth, providing both the 
carbon intermediates for the assembly of macromolecules and the reduced nitrogen 
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for the de novo biosynthesis of nitrogen-containing compounds, including 
nucleotides, glucosamine-6-phosphate and essential amino acids. Mitochondria-
dependent oxidative phosphorylation (OXPHOS) is also used to produce ATP 
starting from glucose, fatty acids or glutamine and serves alongside glycolysis to 
fulfill the high anabolic demand of tumor cells (Obre & Rossignol, 2015). Moreover, 
tumor cells can utilize alternative opportunistic modes to acquire nutrients from the 
environment, such as macropinocytosis of extracellular proteins, engulfment and 
digestion of living cells (“entosis”) and phagocytosis of apoptotic products (Pavlova 
& Thompson, 2016). Such distinct metabolic strategies can vary depending on 
specific surrounding conditions but also on tumor type, referring to both tissue 
origin and cancer subtypes (Elia et al, 2016). In addition, the specific supportive 
tumor microenvironment is emerging as a crucial driver of cancer progression: 
stromal cells are recruited through paracrine stimuli produced by cancer cells and 
are induced to alter their metabolism to in turn fuel cancer growth. Thus, a system 
of dynamic reciprocal interactions between tumor and its TME is constantly 
established.  
 
3.1. The tumor microenvironment: a metabolic cooperation 
and competition in a complex cell and molecular network 
In solid cancers, the tumor microenvironment (TME) constitutes a complex 
network of cells and soluble factors and comprises two main components, that are 
present in variable proportion depending on tumor location and stage: a cell 
component, including fibroblasts, myofibroblasts, mesenchymal stem cells (MSCs), 
adipocytes, pericytes, endothelial cells and cells of haematopoietic origin, both 
lymphoid (T cells, B cells, natural killer cells) and myeloid cells (macrophages, 
neutrophils and myeloid-derived suppressor cells); and the extracellular matrix 
(ECM), composed of collagens, glycoproteins and proteoglycans, scaffolding and 
maintaining the tissue architecture. The neovasculature developing within the 
tumor bulk is also part of the TME structure (Fig. 16). However, it is larger in size e 
less organized compared to its normal counterpart and fails to deeply penetrate the 
tumor, thus resulting in a progressive deprivation of oxygen and energy precursors 
from the periphery toward the core of the mass. The resultant hypoxia and 
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nutritional stress in turn drive a metabolic remodeling in both cancer and neighbor 
host cells, thus creating a pro-tumorigenic TME, mainly characterized by the 
lowering of the extracellular pH due to H+ and lactate released in the extracellular 
compartment (Chiche et al, 2010; Peppicelli et al, 2017). In fact, hypoxic cancer cells 
metabolizing glucose through anaerobic glycolysis produce and secrete lactate, 
which is thereby available for well-oxygenated cancer cells, fueling their 
mitochondrial metabolism. This system is regulated by the expression of 
appropriate intake/release transporters, particularly the lactate exporter 
monocarboxylate transporter 4 (MCT4), whose expression is increased in hypoxic 
tumor regions, and the importer MCT1, up-regulated in normoxic cells (Sonveaux et 
al, 2008). This kind of symbiotic metabolism is also established between cancer and 
surrounding cells (Gupta et al, 2017), making lactate one of the main soluble factors 
acting within this crosstalk (Romero-Garcia et al, 2016): according to the Warburg 
effect, cancer cells produce and secrete large amounts of lactate in the extracellular 
microenvironment, where it can be picked up by cancer-associated fibroblasts 
(CAFs) and MSCs and used as energy source (Koukourakis et al, 2006). The opposite 
process has also been described (Pavlides et al, 2009): tumor cells induce CAFs to 
divert their metabolism toward aerobic glycolysis (namely the "reverse Warburg 
effect"), thereby secreting pyruvate and lactate, which in turn can be consumed by 
Figure 16. Schematic representation of the tumor microenvironment components. MSCs: mesenchymal 
stem cells; CAFs: cancer-associated fibroblasts; MDSCs: myeloid-derived suppressor cells; NK: natural 
killer cells; CSCs: cancer stem cells; ECM: extracellular matrix. Adapted from McCuaig et al, 2017. 
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cancer cells through Krebs cycle and OXPHOS (Chiarugi & Cirri, 2016). The 
presence of high amounts of lactate in the microenvironment results in lowering the 
extracellular pH to 6.0–6.5, thus contributing to acidosis and stimulating malignant 
progression of cancer cells: acidosis, in fact, induces the activation of matrix 
metalloproteinases (MMPs), a family of endopeptidases capable of degrading and 
remodeling the ECM, aiding cell migration and invasion (Kato et al, 2007). In 
addition, lactic acidosis stimulates angiogenesis through the activation of the 
VEGF/VEGFR2 signaling pathway and of endothelial cells, thus promoting tube 
formation (Xu et al, 2002; Hunt et al, 2007; Vegran et al, 2011; Porporato et al, 2012). 
The increased lactic acid production, together with the limited availability of 
nutrients and hypoxia, contributes to the metabolic competition in the TME, which 
particularly affects the tumor-infiltrating immune cell antitumor function, resulting 
in immune suppression: T cell proliferation, differentiation and activation is 
inhibited (Dang et al, 2011; Wang et al, 2014; Chang et al, 2015; Ho et al, 2015; Brand 
et al, 2016) and tumor-associated macrophages (TAMs) are polarized toward the 
pro-tumorigenic M2 phenotype (Colegio et al, 2014; Laoui et al, 2014). 
In addition to lactate transferring, cancer cells are also able to get other essential 
nutrients from the microenvironment (Lyssiotis & Kimmelman, 2017 in press), 
including glutamine, one of the most utilized amino acid: a phenomenon termed 
"glutamine addiction" has been described for cancer cells, which decrease glutamine 
synthesis whereas increase the up-take and catabolism of glutamine produced by 
stromal cells, mainly CAFs and adipocytes (Wise & Thompson, 2010; Ko et al, 2011; 
Lyssiotis et al, 2013; Son et al, 2013; Meyer et al, 2016; Yang et al, 2016). Globally, the 
amino acid metabolism is altered in the TME, as observed for alanin, tryptophan, 
arginin and cysteine (Platten et al, 2012; Zhang et al, 2012; Salimian Rizi et al, 2015; 
Sousa et al, 2016). 
Highly aggressive cancer cells have been shown to have a characteristic pattern 
of lipid deposition, which associates with the presence of several alterations in lipid- 
and cholesterol-associated pathways (Beloribi-Djefaflia et al, 2016): they can either 
increase the up-take of exogenous lipids and lipoproteins or up-regulate their 
endogenous biosynthesis. Moreover, an increased exogenous fatty acid uptake and 
consumption through the fatty acid β-oxidation is also observed, strongly 
contributing to survival and metastatic spreading of cancer cells. Lipid molecules, in 
fact, not only represent a carbon sink, but are also energy-rich molecules that can 
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support cancer growth in a nutrition deprived environment. Within the TME setting 
lipid can be provided as free fatty acids by adipocytes as a result of a metabolic 
reprogramming: in fact, cancer-associated adipocytes are prompted to up-regulate 
lipolysis and release fatty acids, that can be used by cancer cells for both energy 
production and lipid biosynthesis (Romero et al, 2015). Concomitantly, this process 
assures to maintain the terminal electron chain and ATP production in the hypoxic 
TME, as well as to sustain the glycolytic flux thanks to NADP+ generation (Liu et al, 
2010; Santos & Schulze, 2012). 
In addition to the basic molecular building block, non-cancer cells are able to 
release, mainly through the activation of autophagy mechanisms, larger molecules 
such as dipeptides (Chaudhri et al, 2013) and exosomes, small exocytotic vesicles 
containing nutrient cargo, including amino acids, fatty acids and tricarboxylic acid 
cycle metabolites (Zhao et al, 2016; Achreja et al, 2017), that can be used by cancer 
cells to address their biosynthetic and bioenergetic needs. A similar symbiotic 
process has also been described for entire organelles, particularly the transfer of 
mitochondria and/or mitochondrial DNA from the stromal to the cancer cells, 
(Spees et al, 2006; Tan et al, 2015; Moschoi et al, 2016).  
 
3.2. Focusing on the adipose tumor microenvironment: cancer-
associated adipocytes and adipose stem cells  
In recent years, the significant role of adipocytes and adipose progenitors as 
active players in the tumor microenvironment has been demonstrated for many 
types of solid and hematological malignancies: far from being just passive 
bystanders, adipose cells secrete various factors that can mediate both local and 
systemic effects, with particular implication for tumor initiation and growth, as well 
as for local invasion and metastasis. This is due to the establishment of a dynamic 
adipocyte-cancer cell crosstalk that leads to phenotypical and functional changes of 
both cell types, further enhancing tumor progression (Duong et al, 2017). 
Adipose tissue represents one of the main component of the human body and, 
depending on its biological functions, it can be classified into two main types: the 
white adipose tissue (WAT), localized subcutaneously and surrounding visceral 
organs, which is specialized in storing energy and constitutes an important 
endocrine organ, regulating insulin sensitivity and lipid metabolism; and the brown 
adipose tissue (BAT), which can be found in paracervical and supraclav
regions and mainly regulates thermogenesis in response to food intake and cold 
(Cypess et al, 2009; Virtanen 
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2009). Due to their size, adipocytes are considered as the major component of WAT 
and are characterized by the presence of a unique large intracellular lipid droplet 
that constitutes the primary site of energy storage. On the other hand, 
composed of cells with multiple lipid droplets, rich in mitochondria and located in 
highly innervated and vascularized depots. 
generation by thermogenesis and lipid oxidation and specifically express the 
mitochondrial Uncoupling Protein 1 (UCP1) (Cristancho & Lazar, 2011; Cinti, 2012; 
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Figure 17. Schematic representation of the differential morphology of white and brown adipocytes. L: 
lipids; N: nucleus; M: mitochondria. Adapted from Villarroya 
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Reciprocal transformation between the different types of adipose tissue in 
response to a variety of metabolic and environmental challenges have been 
described (Giordano et al, 2014). Therefore, adipose tissue constitutes a dynamic 
organ with a great capacity to adapt its extent depending on the energy status of the 
organism and in response to different pathophysiological conditions (Pellegrinelli et 
al, 2016). Besides its basal function of energy storing, WAT works as an endocrine 
organ, secreting hormones, growth factors, chemokines, pro-inflammatory 
molecules and adipokines, that play a critical role in modulating tumor 
microenvironment: in fact, they mediate many biological processes through both 
local and distant effect that can contribute to tumor growth, differentiation and 
progression. Due to the adipose tissue distribution in different organs, adipocytes 
can often be found in close contact with cancer cells in many tumor types, such as 
breast, colon, renal, prostate and ovarian cancer among others, and such a 
neighborhood commonly associates with a more aggressive tumor behavior (Finley 
et al, 2009; Nieman et al, 2011; Wang et al, 2012; Zhang et al, 2016). Increasing 
evidence, in fact, confirms the establishment of an active crosstalk between adipose 
tissue and cancer cells: the adipocytes closer to malignant cells undergo profound 
phenotypic and functional alterations, such as a decrease in cell number and size 
compared to those distant from the tumor mass. Moreover, at the tumor center, an 
increased ratio of fibroblast-like cells can be observed, thus suggesting a process of 
trans- or de-differentiation of adipocytes induced by cancer cells (Dirat et al, 2011; 
Tan et al, 2011). Consistently, adipocytes co-cultured in vitro with cancer cells show 
delipidation and loss of adipose specific markers such as adiponectin, FABP4 and 
hormone-sensitive lipase (HSL), but they have also been shown to acquire some 
CAF-associated markers (Bochet et al, 2013). In addition, alterations of adipocyte 
secretome have been described, notably the up-regulation of osteopontin, matrix 
metalloproteinase 11 and inflammatory cytokines, such as TNF-alpha, IL-6 and IL-
1β (Ribeiro et al, 2012). Conversely, the secreting adipokines, as well as the released 
fatty acids, are transferred to cancer cells, where they are able to stimulate adhesion, 
migration, and invasion and to sustain energy production, respectively (Nieman et 
al, 2013). Finally, this reciprocal crosstalk results in the local production of specific 
chemokines that can influence immune and inflammatory responses. In particular, 
immune-tolerant macrophages displaying anti-inflammatory responses are 
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recruited, thus contributing to a more favorable microenvironment for tumor 
growth (Sturtz et al, 2014). 
The characteristic plasticity of the adipose tissue is due to the presence of 
adipose-derived stem cells (ASCs) within the stromal vascular fraction, which 
constitute the multipotent progenitor pool of adipose tissue, retaining the stem 
potential to differentiate toward different cell lineages, such as adipogenic, 
osteogenic, condrogenic, myogenic, cardiomyogenic and neurogenic-like cell types 
(Baglioni et al, 2009; Gwak et al, 2009; Zayan et al, 2010). Besides their central role in 
maintaining tissue homeostasis and providing the reservoir of regenerative cells, 
ASCs also influence the tumor microenvironment through the expression and 
secretion of growth factors, cytokines, chemokines and inflammatory factors, thus 
contributing to preserve cancer hallmarks and promoting cancer progression (Ilmer 
et al, 2014; Freese et al, 2015). 
 
3.2.1. The role of mature adipocytes in cancer progression 
Several in vitro and in vivo studies indicate that, in the TME setting, adipocytes 
are modified by cancer cells and acquire metabolic and functional characteristics 
distinct from those of their naïve counterpart. The so called cancer-associated 
adipocytes (CAAs) are then able to support and promote tumor growth, as shown 
in the case of different tumor types, including breast (Elliott et al, 1992; Manabe et al, 
2003), ovarian (Nieman et al, 2011), prostate (Tokuda et al, 2003; Moreira et al, 2015), 
colon (Amemori et al, 2007) cancer and melanoma (Kwan et al, 2014). This 
interaction is mainly mediated by the production and release of different factors by 
CAAs (Fig. 18). They mainly consist of fatty acids and adipokines, the latter ones 
constituting a class of pleiotropic molecules, such as leptin, adiponectin, insulin-like 
growth factor 1 (IGF-1) and hepatocyte growth factor (HGF), implicated in many 
physiological or pathological processes, including cell survival and proliferation, as 
well as cancer invasion and metastasis. 
 CAAs support tumor growth 
Several models of crosstalk between adipocyte and cancer cells have largely 
reported a tumor growth-promoting effect, which seems to mainly be mediated by 
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the interaction of adipokines with their receptors expressed by tumor cells. Leptin is 
a peptide hormone that, besides its neuroendocrine function in controlling food 
intake, can impact a wide range of biological processes, including angiogenesis, 
bone formation and modulation of immune response. Evidence supports the 
potential role for this adipocyte-secreted factor in tumorigenesis: in fact, its receptor 
(Ob-R) is found highly expressed in many cancers, and several in vitro studies 
showed that leptin can induce cancer cell proliferation via activation of ERK1/2 and 
JNK pathways (Garofalo & Surmacz, 2006). On the other hand, it has been observed 
that the production of adiponectin, another major adipokine involved in the 
regulation of glucose levels and fatty acid oxidation, is reduced in CAAs, thus also 
contributing to cancer cell proliferation. In fact, adiponectin acts by mediating 
antiangiogenic and tumor growth-limiting effects that are opposite to those of 
leptin, such as activation of AMPK, inhibition of PI3K/Akt and ERK1/2 pathways, 
down-regulation of leptin-induced STAT3 phosphorylation, inhibition of NF-kB and 
Wnt/β-catenin signaling and decrease of ROS production (Dalamaga et al, 2012). 
Thus, the leptin:adiponectin ratio seems to be the major factor influencing tumor 
growth. Adipocytes also produce growth factors, particularly IGF-1 and HGF, 
which are able to promote cell growth and survival through the binding to their 
specific receptors expressed by tumor cells. The IGF1/IGF-1R interaction, which 
activates the growth-inducing PI3K/Akt and ERK pathways, has been shown to 
regulate breast cancer cell growth (D'Esposito et al, 2012), whereas HGF seems to 
mediate a paracrine interaction between adipocytes and tumor cells expressing the 
c-Met receptor, thus promoting tumor progression, as observed in breast and 
ovarian cancer (Rahimi et al, 1994; Takayama et al, 1997; Edakuni et al, 2001; Wong et 
al, 2001). 
 
Figure 18. Schematic representation of the crosstalk and the reciprocal functional influence between 
adipocytes and cancer cells within the TME. Adapted from Park et al, 2014. 
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As already mentioned, cancer cells are capable to induce a metabolic shift from 
oxidative phosphorylation to glycolysis in cancer-associated fibroblast as well as in 
the other cells of the tumor stroma, resulting in the production of lactate and 
pyruvate, factors that sustain cancer metabolism and proliferation. This process may 
represent one of the mechanisms by which adipocytes are able to fuel cancer 
growth, since they have been shown to release lactate through the monocarboxylate 
transporters, particularly under hypoxic conditions (Pérez de Heredia et al, 2010). 
However, lipids seem to be the main source of energy provided by adipocytes to 
cancer cells: as described in different types of solid cancers, CAAs appear smaller in 
size and with a decreased lipid content, thus suggesting that a lipolytic process is 
induced by cancer cells, finally resulting in adipocyte delipidation and release of 
free-fatty acids (FFAs), which can be in turn metabolized by tumor cells through β-
oxydation (Dirat et al, 2011; Nieman et al, 2011, 2013; Park et al, 2014; Balaban et al, 
2017; Wang et al, 2017; Wen et al, 2017). The existence of such an active exchange of 
FFAs between tumor cells and CAAs is supported by the observation of an 
increased level of free acid-binding proteins (FABPs) in several cancers, including 
breast, prostate, ovarian and colorectal carcinomas (Guaita-Esteruelas et al, 2017 in 
press).  
The dynamism of modifications and interactions taking place within the tumor 
microenvironment requires a steady supply of oxygen and nutrients to assure 
tumor growth and expansion. Angiogenesis is a crucial process for supplying 
oxygen and nutrient delivery to the tumor mass. This process is tightly regulated by 
both tumor and stromal cells, including adipocytes: they can actively participate in 
angiogenic modulation through the direct production of the classical angiogenic 
factors (i.e. VEGFA) (Mick et al, 2002) or the release of leptin, which has been shown 
to directly promote proliferation and differentiation of endothelial cells and to up-
regulate VEGF in cancer cells (Gonzalez-Perez et al, 2010, 2013). 
 CAAs promote cancer invasion and metastasis 
Besides their role in controlling tumor cell proliferation and survival, growth factors 
and cytokines released within the TME strongly contributes to tumor cell migration 
and invasion, orchestrating the complex cascade of events underlying dissemination 
and metastasization (Odenthal et al, 2016). In this setting, adipocytes seem to play a 
crucial role, contributing to the remodeling of extracellular matrix and promotion of 
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tumor homing. Several in vitro models showed that the presence of CAAs is able to 
increase the invasive ability of cancer cells in different types of solid tumors, and 
this is mostly mediated by the secretion of soluble factors (Dirat et al, 2011; Tan et al, 
2011; Ribeiro et al, 2012; Bochet et al, 2013; Moreira et al, 2015). The most abundantly 
adipocyte-secreted cytokines are represented by interleukin 6 (IL-6), IL-8 and 
monocyte chemotactic protein-1 (MCP-1): they are produced at high levels by CAAs 
and determine the establishment of a chronic inflammatory state in the tumor-
surrounding adipose tissue, which promotes tumor dissemination, as well as cancer 
cell homing and seeding at distant organs (Finley et al, 2009; Dirat et al, 2011; 
Nieman et al, 2011; Pramanik et al, 2013; Laurent et al, 2016). In addition, leptin 
secretion also seems to contribute to cancer cell migration and invasion via IL-18 
expression and secretion (Li et al, 2016) and to affects both innate and adaptive 
immunity, thus facilitating the immunomodulatory mechanisms allowing tumor 
escape (Delort et al, 2015). Furthermore, fatty acid transfer between CAAs and 
cancer cells via exosome secretion has been shown to further sustain migration and 
invasion (Lazar et al, 2016). 
Besides adipokines and growth factors, adipocytes also produce some of the 
components of the ECM, which undergoes significant structural and molecular 
remodeling during tumor progression, driving cell migration. In particular, CAAs 
have been shown to up-regulate their secretion of collagen VI under cancer cell 
induction (Iyengar et al, 2005) and to produce a number of MMPs, predominantly 
MMP-11 (Chavey et al, 2003), which is actively involved in cancer migration and 
invasion (Zheng et al, 2016). MMp-11 also seems to directly affect adipocyte 
functions by negatively regulating adipogenesis and enhancing de-differentiation, 
thus leading to the accumulation of fibroblast-like cells in the tumor 
microenvironment (Andarawewa et al, 2005). 
 
3.2.2. The role of ASCs in cancer development, growth and 
progression 
As discussed above, adipose tissue is a rich source of ASCs, which are part of the 
ubiquitously distributed mesenchymal stem cells (MSCs), constituting the pool of 
stem and progenitor cells responsible for tissue homeostasis, repair and 
regeneration. To exert such a function, MSCs are recruited by the local 
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microenvironment, being able to migrate along chemoattractant gradients (Ilmer et 
al, 2014). As already discussed, in the tumor microenvironment an exchange of 
soluble factors is dynamically established, thus facilitating the recruitment of 
immunomodulatory components and stromal cells of various origin, contributing to 
some of the hallmarks of cancer, such as angiogenesis, invasion and metastasis, and 
apoptosis resistance. There is increasing evidence that ASCs might be crucial in 
supporting cancer development and progression, influencing and being influenced 
by the tumor microenvironment (Freese et al, 2015). Many studies, in fact, showed 
that ASCs recruited to the TME can differentiate toward different cell types, such as 
endothelial cells, vascular complexes and tumor stroma, facilitating cancer cell 
growth (Muehlberg et al, 2009; Kucerova et al, 2011; Chandler et al, 2011, 2012; 
Nowicka et al, 2013). CXCL12 (also known as stromal-derived factor-1 - SDF-1) and 
its receptor CXC Receptor-4 (CXCR4) axis might be involved in driving ASC 
migration and incorporation into the TME. As recently shown, high levels of 
CXCL12 in the TME can attract CXCR4-positive immune and stromal cells to the 
tumor site to assist tumor development (De Palma et al, 2005; Orimo et al, 2005; Jin et 
al, 2006; Du et al, 2008; Beider et al, 2014). The other way round, CXCL12 secreted by 
ASCs in the TME strongly promotes tumor proliferation, migration and invasion 
through multiple signaling pathways triggered by the interaction with CXCR4 
expressed by cancer cells (Zhao et al, 2010; Ji et al, 2013). CXCL12 is a homeostatic 
chemokine normally controlling hematopoietic cell trafficking, adhesion, immune 
surveillance and development through the interaction with its cognate receptor 
CXCR4, a member of the seven-transmembrane domain G-protein–coupled receptor 
(GPCR) superfamily. Both are overexpressed in various cancer types and their 
interaction leads to the activation of intracellular pathways regulating cell survival, 
proliferation and chemotaxis, such as MAPK, PI3K/AKT, NF-kB (Guo et al, 2016) 
(Fig. 19). In addition, such interaction has been correlated with angiogenesis and 
EMT induction, promoting cancer metastasis (Guo et al, 2016). Moreover, CXCL12 is 
physiologically expressed by mesenchymal stroma niches in different organs, 
including liver, lung and bone marrow, where CXCR4-positive cancer cells can be 
recruited to initiate metastasis (Guo et al, 2016). Recently it has been shown that 
CXCL12 can also bind CXCR7 with high affinity (Ghanem et al, 2014), thus 
mediating different potential effects than CXCR4: CXCR7 overexpression has been 
reported in different cancer types (Hattermann et al, 2010; Deutsh et al, 2013; Hu et  
 al, 2014; Lin et al, 2014; Wu 
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growth (Pinilla et al, 2009; Walter et al, 2009; Devarajan et al, 2012; Welte et al, 2012; 
Scherzed et al, 2013; Reggiani et al, 2017). 
Finally, ASCs seem to be crucial in regulating the immunomodulatory 
mechanisms allowing tumor cells for thwart immune surveillance: they inhibit 
natural killer (NK) cell activation and suppress B-cell functions (Bochev et al, 2008) 
and secrete various cytokines, including IL-4, IL-10, IL-8, TGF-β, which contribute to 
regulate T cell activity and to create a tumor microenvironment characterized by 
specific modulation of inflammation, thus promoting tumorigenic activity 
(Razmkhah et al, 2010). 
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4. Tumor progression and metastatic colonization: circulating 
tumor cells as biomarkers of tumor evolution 
The main cause of cancer-related death in patients is represented by metastasis: 
cells from primary tumors acquire the ability to disseminate through the blood 
circulation and to colonize distant organs, giving rise to a systemic disease and 
making treatments ineffective in most of the cases. Differently from what originally 
hypothesized, the acquisition of metastatic traits is an early event in the 
evolutionary story of a tumor, since invasive and motile cells can enter the 
circulation and seed distant organs long before a tumor is diagnosed, and the 
presence of metastatic disease at diagnosis almost always associates with poor 
prognosis, as well as development of chemoresistance. Current evidence suggests 
that metastasis-initiating cells are pre-selected within the primary tumor through 
genetic and, predominantly, epigenetic changes, undergoing further selection under 
the stress pressure related to tissue invasion, immune surveillance or hypoxia. This 
is consistent with the observation that metastasis share some genomic traits 
compared to their primary tumor and support the hypothesis that a clonal 
expansion in the primary tumor itself gives rise to metastasis-competent cells, that 
continue to evolve in parallel during their dissemination to distant organs (Klein, 
2009; Greaves & Maley, 2012; Vanharanta & Massagué, 2013; Gundem et al, 2015; 
Naxerova & Jain, 2015). 
Experimental and clinical observations indicate that metastatic colonization is a 
highly inefficient process, in which only a minority of the cells shed by the tumors 
can survive and form macrometastases. This is due to multiple obstacles that 
circulating tumor cells (CTCs) have to face before reach and seed a distant site, 
including escaping their primary microenvironment and invading the surrounding 
tissue, successfully entering the circulation, adapting to a new microenvironment 
and surviving in a latent dormancy state, to eventually break out as an overt 
metastasis (Fig. 20) (Massagué & Obenauf, 2016). Therefore, the metastatic process 
follows multiple steps and shows a number of bottlenecks driving the fate of the 
most aggressive cells: in the early phases, cytoskeletal rearrangements, combined 
with ECM remodeling and interactions with the supportive tumor niche, allow 
cancer cells to invade and migrate through the stroma. In response to various 
signaling factors released by the surrounding stromal cells, cancer cells can undergo 
epithelial-to-mesenchymal 
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achieved and a residual disease is left behind. This is mainly due to the capability of 
tumor cells to adapt their intracellular pathways under the stress of therapy, 
expressing a large number of secreted factors (known as therapy-induced 
secretome) able to protect the drug-sensitive cells and to selectively stimulate the 
drug-resistant minority (Holohan et al, 2013). Therefore, preventing metastasis 
rather than treat them would be more effective in high-risk patients. In this scenario, 
liquid biopsy represents the new frontier for cancer early diagnosis, prognosis and 
treatment. This is a minimally invasive procedure carried out during a standard 
blood draw, accessing different types of tumor material, including CTCs, cell-free 
DNA of tumor origin (ct-DNA), RNA and exosomes, feasible for molecular 
characterization. Analyzing this material may allow to profile the single patient 
tumor evolution, consistently with the idea of personalized medicine. 
 
4.1. Biology, detection and clinical implications of circulating 
tumor cells 
Circulating tumor cells can be considered as a surrogate of tumor sample that 
and reflect tumor evolution during progression and metastatic potential, as well as 
the effectiveness and progression of systemic therapies, allowing for monitoring 
patients during the follow up or after surgery of during treatment. Indeed, CTCs 
have been proposed as real-time "liquid biopsy", since they could allow to profile 
the disease complexity at any stage of tumor progression (Alix-Panabières & Pantel, 
2013). Several new high-throughput technologies have been developed to analyze in 
very deep detail the functional and phenotypic traits of heterogeneous cell 
populations at the single-cell level. This has largely simplified the study of CTC 
biology, improving the knowledge about the mechanisms underlying their ability to 
disseminate and providing new information to make cancer treatment more 
relevant and patient-centric. 
 
4.1.1. CTC Biology 
As already mentioned, CTCs have to overcome a number of physiological 
hurdles to escape their primary site and enter the blood flow. According to the most 
widely recognized theory, cells undergo EMT to actively dissociate from the 
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primary tumor and enter the blood vessels (Pantel & Speicher, 2016), under 
paracrine signals coming from the surrounding microenvironment. Cytoskeletal 
changes, together with the loss of tight and adherens junctions, underlie the loss of 
cell polarity and enable epithelial cells to become more invasive and motile (Joosse 
et al, 2015). This process typically associates with the down-regulation of epithelial 
markers, such as EpCAM and E-cadherin, the alteration of keratin expression and 
the up-regulation of mesenchymal markers, such as vimentin. The concomitant up-
regulation of matrix metalloproteinases (MMPs) contributes to facilitate migration 
through the local ECM and intravasation (Lamouille et al, 2014). This is consistent 
with the observation that CTCs with mesenchymal traits predict poor outcome and 
resistance to standard chemotherapy (Aktas et al, 2009; Yu et al, 2013; Krawczyk et al, 
2014; Li et al, 2017). However, the role of EMT in CTCs is still unknown: on one 
hand, tumor cells undergoing EMT seem to be more resistant against share stress 
(Mitchell & King, 2013), whereas on the other one, several studies have correlated 
the overexpression of EpCAM to an increased risk of metastasis and reduced 
survival (Cimino et al, 2010; Spizzo et al, 2011) and have demonstrated the 
prognostic relevance of EpCAM-positive CTCs (Rack et al, 2014; Janni et al, 2016). It 
might be possible that these cells have some degree of co-expression of epithelial 
and mesenchymal markers, consistent with their plasticity (Alix-Panabières et al, 
2017). Indeed, increasing evidence indicates that CTCs represent heterogeneous cell 
populations (Lapin et al, 2017; Lindsay et al, 2017). This is consistent with the fact 
that cancer EMT occurs through a spectrum of intermediate states, from the full 
transition taking place at the tumor invasive front to the complete absence in the 
main tumor bulk (Nieto et al, 2016). Thus, CTCs may derived from cells that 
underwent EMT in the primary tumor or may acquire intermediate EMT 
phenotypes in circulation, allowing for cell survival.  
In addition to single CTCs, CTC clusters, namely circulating tumor microemboli 
(CTM), can also be found in patients' blood: they are groups of 2 to more than 50 
cells able to extravasate and generally correlate with very poor clinical outcome 
(Hou et al, 2012; Aceto et al, 2014, 2015; Au et al, 2016). They are thought to have 
greater metastatic potential and to provide a survival advantage to single cells, since 
their cell junctions may help to avoid anoikis (Paoli et al, 2013). In addition, single 
CTCs or clusters can aggregate with platelets, thus facilitating extravasation and 
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protecting cell from mechanical stress and immune surveillance (Strilic & 
Offermanns, 2017). Moreover, CTCs are able to suppress T-cell proliferation and 
cytokine production by expressing PD-L1 (Mazel et al, 2015; Nicolazzo et al, 2016; 
Anantharaman et al, 2016).  
Despite all these survival strategies, CTCs remain a rare event: they persist in the 
circulation for an estimated time of 1.0-2.4 hours (Meng et al, 2004) and can be 
detected in a range of 1-10 cells per millions (106–107) of surrounding normal 
peripheral mononuclear blood cells in the circulation of patients with advanced 
disease (Alix-Panabieres et al, 2012). Thus, isolation and characterization remain 
challenging, particularly in order to determine the traits underlying cell 
heterogeneity and to identify the specific markers of metastatic properties. 
 
4.1.2. CTC isolation and characterization 
Over the past two decades, many techniques have been developed for CTC 
detection and novel strategies are continuously proposed to improve isolation yield. 
CTC enrichment relies on two main approaches: the use of label-dependent 
techniques, exploiting the detection of surface marker through immunoselection; 
and the application of label-independent techniques based on unique mechanical 
and physical differences of CTCs when compared to the blood cells, including size, 
deformability and electrical properties (Fig. 21) (Joosse et al, 2015; Salvianti et al, 
2016). 
The most widely used technology is represented by the CELLSEARCH® system 
(Veridex, USA), which is based on the immunomagnetic capture of EpCAM-
expressing cells, identifying as CTCs cells positive for nuclear DAPI (4′,6-diamidino-
2-phenylindole) and cytokeratins, and negative for CD45 (lymphocyte marker). This 
system allows CTCs automatic count and it has been approved by the USA FDA for 
the use of CTC enumaration as prognostic marker in metastatic breast, colon and 
prostate cancers (Cristofanilli et al, 2005; Cohen et al, 2008; de Bono et al, 2008). 
Although this is the only clinically validated platform for CTC analysis, analogous 
EpCAM-based systems are also available (Nagrath et al, 2007; Talasaz et al, 2009; 
Saucedo-Zeni et al, 2012). However, all these methods show the intrinsic bias of the  
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lack of univocal CTC biomarkers: EpCAM itself is not expressed by all tumor types 
and, as previously described, a subset of epithelial cancer cells undergo EMT, likely 
losing the expression of this epithelial marker. Alternatively, several approaches 
relying on physical properties of cells have been developed, such as the use of 
density gradient centrifugation, which allows to separate cells on the basis of the-
sedimentation coefficient (Low & Wan Abas, 2015). Size-based methods, instead, 
exploit the dimensions of CTCs, which are generally bigger than the other blood 
cells, with a diameter ranging from 17 to 52 µm. Among all filtration devices, those 
employing microfilters with a selective porous membrane (8 µm pore diameter), 
represent a relatively simple way to obtain an enriched pool of cells within a single 
processing step, preserving cell integrity for CTC identification and further 
characterization (Vona et al, 2000; Desitter et al, 2011). In addition, CTC clusters can 
also be separated this way. However, this approach shows some drawbacks, 
including the loss of smaller tumor cells, the risk of filter clogging due to high 
concentration of blood cells and the requirement of CTC detachment from the 
membrane to perform downstream analysis. Other methods combining cell size and 
microfluidics have been developed (Hou et al, 2013; Sollier et al, 2014), as well as 
size- and deformability-based technologies (Tan et al, 2009, 2010; Che et al, 2017). 
Moreover, a chip for the specific isolation of CTC cluster is available, based on the 
separation by different flow speed  compared to single cells (Sarioglu et al, 2015). 
Figure 21. Schematic representation of CTC detection approaches and downstream applications for 
molecular characterization. Adapted from Cabel et al, 2017. 
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CTC identification and enumeration are commonly performed  by morphologic 
investigation together with fluorescence immunocytochemistry (ICC). However, 
conventional microscopic examination is cost- and time-consuming, whereas 
automated cell image capturing and analysis systems present filter set limitations 
(Joosse et al, 2015). The use of multiplex PCR could help in targeting the numerous 
tumor-associated mRNA transcripts, such as EMT-associated and stem cell markers 
for CTC identification (Kasimir-Bauer et al, 2012). Another strategy is represented by 
the enumeration and analysis of proteins specifically secreted by viable tumor cells 
(EPISPOT, EPithelial Immuno SPOT) through a system of fluorochrome-labeled 
antibodies targeting the proteins of interest (Alix-Panabieres et al, 2007; Alix-
Panabieres, 2012). 
CTC enrichment and identification represents the first step to eventually obtain 
single cells suitable for molecular and functional characterization, since simple 
enumeration does not to reflect the complexity of genetic and epigenetic changes 
occurring during tumor progression. Many strategies have been applied for this 
purpose (Shapiro et al, 2013; Navin, 2014), including manual low-throughput 
micromanipulation and laser-capture microdissection, flow cytometry and the most 
recently developed semiautomated DEParray (Di-Electro-Phoretic Array; Silicon 
Biosystems, Italy) system (Peeters et al, 2013). Once isolated, CTCs can be analyzed 
for chromosomal rearrangements or changes in gene copy number by using 
techniques such as interphase fluorescence in situ hybridization (FISH) and array-
CGH (comparative genome hybridization). Additionally, next generation DNA 
sequencing can be performed to study the CTC genome-wide mutation spectrum 
(Heitzer et al, 2013; Carter et al, 2017). Other traditional techniques have been 
applied to CTC characterization, such as RNA in situ hybridization, multiplexed 
quantitative PCR and gene expression microarray (Smirnov et al, 2005; Xi et al, 2007; 
Payne et al, 2012; Yu et al, 2013); moreover, the increasing feasibility of the advanced 
single-cell expression profiling approaches are now allowing to shed new light on 
CTC clonal evolution and heterogeneity (Sandberg, 2013; Lohr et al, 2014; Wang et 
al, 2014; Miyamoto et al, 2015). A question remain about how and when such 
techniques will become predictive, specific and inexpensive enough to be adopted 
for the routinely clinical practice. 
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Due to CTC rarity, their functional characterization still remains technically 
challenging. Cell line and organoid culture have been established with low 
efficiency and are available only for a handful of cancers (e.g. Cayrefourcq et al, 
2015). CTC functionality has been tested both in culture and in vivo in mouse 
xenograft models, measuring the invasive and metastatic properties of isolated cells 
(Baccelli et al, 2013; Friedlander et al, 2014), as well as the response to 
chemotherapeutics (Hodgkinson et al, 2014; Yu et al, 2014; Khoo et al, 2016). 
However, further studies are needed to standardize the current culture techniques 
and in vivo strategies. 
 
4.1.3. Clinical validity and utility of CTCs 
The diagnostic, prognostic and predictive value of CTC has been investigated in 
various cancer types, demonstrating a clinical validity for CTC detection and 
characterization, at least in some solid tumors (Cabel et al, 2017).  
CTC count, mainly based on the use of the CELLSEARCH® technology, has been 
investigated as diagnostic in early non-metastatic cancers: most of the studies 
reported very low CTC detection rate, depending on the limited specificity and 
sensitivity on the technique (Loh et al, 2014; van Dalum et al, 2015; Bidard et al, 
2016). The ISET filtration system, instead, showed better performances in lung 
cancer early detection and differential diagnosis (Ilie et al, 2014; Fiorelli et al, 2015). 
On the contrary, high level of evidence showed a strong prognostic value for CTC 
count determined by CELLSEARCH®: in both metastatic and non-metastatic 
cancers, particularly breast, colon, prostate and lung cancer, elevated baseline CTC 
count represents an independent prognostic factor for both overall survival and 
free-progression survival (Cabel et al, 2017). Moreover, several reports suggest a 
predictive value for CTC detection in monitoring the efficacy of therapies: 
particularly in metastatic breast, colon and prostate cancers, a decreased CTC count 
after treatment associates with better prognosis (Cristofanilli et al, 2004; Cohen et al, 
2008; de Bono et al, 2008; Hou et al, 2012; Bidard et al, 2014; Goldkorn et al, 2014). 
However, CTC analysis remains still limited when applied to non-metastatic 
cancers, due to the low rate of CTC detection and to the significance to be 
attributable to their presence in non-invasive stages of tumors. 
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Although its clinical validity, CTC detection has not been approved for the 
routinely clinical practice, since a clinical utility, meaning an improvement in 
patient's outcome, has not yet been validated. Several ongoing clinical trials are 
investigating the utility of CTC in the therapeutic decision, basing on CTC count 
and variation, as well as on the presence of molecular processes and biomarkers 
specifically related to CTCs or to the metastatic spread (Cabel et al, 2017). The 
improvement in the sensitivity of CTC detection techniques and the development of 
in vitro (CTC cultures) and in vivo xenograft models for drug screening will be 
crucial to finally launch CTCs in the clinical practice. 
 
4.2. CTCs in adrenocortical carcinoma 
To date, only one preliminary study has been performed to assess the presence of 
circulating tumor cells in the peripheral blood of patient with adrenocortical 
carcinoma compared with benign adenomas (Pinzani et al, 2013). In a cohort of 24 
patients (14 ACC and 10 ACA), CTCs were isolated by using the ScreenCell® 
filtration device and detected in all ACC samples, unlike in ACA samples, thus 
indicating the potential use of CTC detection for the differential diagnosis of 
adrenocortical tumors. Adrenocortical origin of isolated cells was confirmed by 
immunocytochemistry performed against typical neuroendocrine markers, such as 
synaptophysin and MART-1/MelanA, but also against the more adrenocortex-
specific Steroidogenic Factor-1 (SF-1) (Fig. 22). CTC count in pre-surgical and post-
surgical samples of ACC patients revealed that surgery significantly affects the 
number of CTCs (Fig. 23A), even if no significant correlation with the length of 
follow-up was evident. When patient clinical features were considered, a 
Figure 22. CTC detection in blood samples 
from ACC patients. A–F: Hematoxylin/eosin 
staining was performed on filters to identify 
and count CTCs on the basis of established 
morphological criteria (cell size > 16 µm; 
nucleocytoplasmic ratio > 50%; irregular 
nuclear shape; hyperchromatic nucleus; 
basophilic cytoplasm. Positivity related to 
MART-1 (G), synaptophysin (H), and SF-1 (I) 
immunocytochemistry confirmed CTC 
adrenocortical origin. Adapted from Pinzani 
et al, 2013. 
Introduction 
69 
statistically significant linear correlation was found only with the tumor diameter 
(R2=0.362; R=0.602; P=.023; n=14), while no correlation was present with the other 
parameters analyzed, such as Ki67, age, stage and Weiss score. Moreover, CTC 
number were significantly higher in patients with metastatic disease (Fig. 23B). 
 
 
Although limited by the small cohort of patients analyzed, this preliminary study 
suggests that CTCs may be a useful marker in aggressive/metastatic ACC for both 
prognosis and monitoring of progression and response to treatments. Therefore, in 
the setting of non-invasive liquid biopsy, CTCs could provide meaningful 
information to elucidate the metastatic process and the different molecular and cell 
factors involved. The possibility to investigate gene and protein expression, as well 
as epigenetic changes, starting from single-cell samples, would help in identifying 
specific biomarkers associated with CTC heterogeneity and metastasizing potential 
(Salvianti & Pinzani, 2017; Siravegna et al, 2017). This knowledge may aid the 
development of more effective treatments specifically targeting the metastatic 
disease. Moreover, information provided by CTC analysis could be complemented 
by additional genomic information coming from cell-free circulating tumor DNA, 
which has been recently demonstrated to be detectable in blood sample also in ACC 
(Creemers et al, 2017). Thus, the "liquid biopsy" analysis would provide a more 
comprehensive understanding of ACC heterogeneity and patient-related disease 
progression. 
Figure 23. A): Absolute values of CTC count 
evaluated in ACC patients show a significant 
decrease of CTC number after surgery in 
samples collected during follow-up compared 
to pre-surgery samples. B): Stage and diameter 
were used to stratify ACC patient (n=14) in two 
classes, using stage 4 or diameter median value 
as cut-off. Adapted from Pinzani et al, 2013. 
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OBJECTIVES 
Molecular features underlying adrenocortical carcinoma heterogeneity and 
evolution are just being unraveling, showing that driver gene mutations, epigenetic 
alterations and dysregulation of signaling pathways related to cell survival, growth 
and proliferation, play a crucial role in determine malignancy. However, even if 
molecular alterations are essential to provide a survival and growth advantage to 
cancer cells within the tumor mass, they cannot exhaustively enucleate the 
mechanisms by which malignant cells acquire the ability to migrate and metastasize 
to distant sites, thus allowing cancer progression. The adaptation of cell metabolism 
to dynamically changing environmental conditions related to tumor evolution 
represents a key hallmark of cancer. Tumor microenvironment constitutes the ideal 
soil to establish a constant crosstalk between tumor and stromal cells, thus inducing 
reciprocal metabolic and functional alterations, eventually supporting tumor 
growth and progression. Studying the dynamics of such interactions would help in 
elucidating cancer biology and developing more effective targeted therapies 
addressing cancer-microenvironment crosstalk. Since adrenal glands present a 
substantial component of adipose tissue, the interactions with the surrounding 
adipose microenvironment may play a pivotal role in adrenocortical tumorigenesis 
and ACC progression, as widely described for other tumor types, where cancer cells 
are in close contact with adipocytes. 
The first objective of this thesis (Results - Part I) was to reproduce in vitro a 
system of reciprocal interactions between the adrenocortical tumor cell line NCI-
H295R and the human adipose-derived stem cells (ASCs) or in vitro differentiated 
adipocytes in order to evaluate: 
i. the paracrine effects of the adipose component on H295R cell behavior, 
including variations of cell proliferation and motility/migration ability; 
ii. the influence of H295R cells on ASC proliferation, gene expression and ability 
to effectively differentiate toward a white mature and functional adipocyte 
phenotype 
iii. the potential cell signaling pathways and factors involved in this reciprocal 
interaction. 
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The second part of the thesis (Results - Part II), instead, investigates the 
possibility to isolate and characterize circulating tumor cells (CTCs) in blood 
samples from patients with adrenocortical carcinoma, in order detect specific 
molecular features to be compared with those of the primary tumor, allowing to 
track tumor evolution and progression. Particularly, the objectives included: 
i. the collection of blood samples from ACC patients, possibly at different time 
points during the follow-up, for CTC isolation, identification and 
enumeration;  
ii. the cytological analysis of CTCs to confirm their adrenocortical origin; 
iii. the design of an experimental workflow to obtain CTC DNA to perform 
downstream analysis with techniques such as targeted next generation 
sequence (NGS) and digital-droplet PCR (ddPCR) and to confirm the presence 
of the original mutations previously found in the primary lesions. 
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RESULTS 
PARTI I - Investigating the crosstalk between adrenocortical 
carcinoma cells and adipose microenvironment 
 
Materials and methods 
 Cell cultures. The human adrenocortical carcinoma cell line H295R was 
obtained from the American Type Culture Collection (ATCC) and cultured in 
DMEM/F-12 medium with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin-100 
µg/ml streptomycin and a mixture of insulin/transferrin/selenium (ITS) (Sigma-
Aldrich). Human primary adipocyte-derived stem cells (ASCs) were isolated from 
the stromal vascular fraction (SVF) derived from subcutaneous adipose tissue 
biopsies as described elsewhere (Baglioni et al, 2009): briefly, adipose tissue biopsies 
underwent mechanic and enzymatic processing until obtaining the SFV, which was 
plated and, after having removing the non-adherent contaminating cells, cultured in 
DMEM with 20% FBS, 2 mM L-glutamine, 100 U/ml penicillin-100 µg/ml 
streptomycin and 1 µg/ml amphotericin-B (Sigma-Aldrich). All cells were incubated 
at 37°C in a humidified 5% CO2 atmosphere. 
 Co-culture system. H295R and ASCs where co-cultured in the setting of 
different experiments by using a specific tissue culture inserts for 6-well plates 
having a porous membrane with 0,4 µm diameter pores (ThinCertTM, Greiner Bio-
One), thus allowing to maintain the two cell types separated, while the medium 
soluble components can be exchanged (Fig. R1). H295R cells and ASCs were seeded, 
except where differently indicated, in the cell culture inserts (105cells/insert) and in 
the well (8×104) respectively, each in its own complete medium. At the starting time 
of the co-culture, the inserts containing H295R were transferred into the wells 
containing ASCs and all cells were grown in DMEM plus 10% FBS. H295R and 
ASCs cultured alone in the same conditions of the co-cultured ones were used as 
relative controls for each type of assay. 
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 Viable cell count. H295R and ASCs seeded in the co-culture system were 24 
hour starved and put together to start the co-culture. At different  time points (0, 1, 
2, 3, 6, 9 days) cells were trypsinized and counted by an haemocytometer, after dead 
cell exclusion with trypan blue staining. The mean number of viable cells was 
obtained by counting four replicates in at least three different experiments. 
 Glucose up-take measurement. H295R and ASCs, co-cultured or grown alone 
for 7 days, were washed twice with PBS and incubated overnight in serum free and 
low glucose (0,55 mM) medium. After PBS wash, cells were incubated with Hepes 
buffer (140 mM NaCl, 20 mM Hepes-Na pH 7.4, 2,5 mM MgSO4, 1 mM CaCl2, 5 
mM KCl) containing 2-deoxy-[3H]D-glucose [1µCi/µl] (Perkin-Elmer) for 10 
minutes at 37°C. Cells were then washed with cold PBS and were lysed in 100 mM 
NaOH for 1 hour at 37°C. After resuspension of samples in Insta-Gel Plus cocktail 
(Perkin-Elmer), radioactivity was measured on a scintillation beta counter. 
 Evaluation of conditioned media. Conditioned media related to 72 hour 
mono- or co-culture of both H295R and ASC were assessed to quantify glucose, 
lactic acid and cortisol content by using a routinely detection method at the central 
analysis laboratory (Azienda Ospedaliero Universitaria Careggi, Florence). 
 Transmission electron microscopy. After 7 day mono- or co-culture, H295R 
and ASCs were trypsinized and centrifuged at 1200 rpm for 5 minutes. Pellets were 
fixed in cold 2.5% glutaraldehyde and 2% formaldehyde in 0.1 M sodium cacodylate 
buffer (pH 7.4) for 1 h at room temperature, and post-fixed in cold 1% osmium 
Figure R1. Schematic representation of the described co-culture system 
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tetroxide in 0.1 M phosphate buffer (pH 7.4) for 1 h at room temperature. Pellets 
were dehydrated in graded acetone, passed through propylene oxide, and 
embedded in epoxy resin. Ultrathin sections were stained with gadolinium acetate 
and alkaline bismuth subnitrate and examined under a JEM 1010 electron 
microscope (Jeol) at 80 kV. 
 In vitro adipocyte differentiation and lipid content quantification. ASCs 
were seeded onto glass coverslips in 6-well plates (5×104 cells/well) and cultured, 
alone or together with H295R (105 cells/insert), in the presence of adipogenic 
medium (DMEM plus 10% FBS, 0,5 mM 3-isobutyl-1-methylxanthine, 1 mM 
dexamethasone, 10 mM insulin and 1µM rosiglitazone - DIM cocktail). ASCs 
cultured in DMEM with 10% FBS were used as negative control. After 10 day 
differentiation, the intracellular lipid content was measured by AdipoRedTM assay 
according to the manufacturer’s instructions. Fluorescence emission was measured 
by 485/572 nm excitation/emission. The specific absorbance related to the 
differentiated adipocytes was calculated as fold increase on the unspecific 
absorbance related to the undifferentiated ASCs. Coverslips were finally mounted 
on microscope slides in the presence of ProLong® Gold antifade reagent with DAPI 
(Thermo Fisher Scientific Inc.) and the fluorescence related to the lipid droplets was 
acquired with a Leica DM4000 epifluorescence microscope (Leica Microsystems 
GmbH). This same protocol was slightly modified to obtain in vitro differentiated 
mature adipocytes suitable for co-culture with H295R: ASCs were cultured for 7 
days in the presence of DIM cocktail and then cultured alone or in the presence of 
H295R for additional 9 days in complete DMEM/F12. The same experimental 
procedure already described was used for measuring the intracellular lipid content 
and to acquire fluorescence images. 
 SDS-PAGE and Western Blot Analysis. After 7 day mono- or co-culture, 
cells were lysed in RIPA buffer (20 mM Tris pH 7.4, 150 mM NaCl, 0,2 mM EDTA, 1 
mM OVA, 0,5% Triton-100 in ddH2O) supplemented with phosphatase and 
protease inhibitors. After protein measurement by Coomassie method, equal 
amounts of proteins for each sample (30 µg) were separated by SDS–PAGE and 
transferred onto PVDF membranes (Immobilon, Merck Millipore). Each membrane 
was incubated overnight at 4°C with primary antibodies, at the appropriate 
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dilutions, against the following proteins: IGF-1Rβ, Fascin-1, RhoA, GAPDH, Actin, 
GLUT-1, GLUT-4, SDF-1/CXCL12 (Santa Cruz Biotechnology, Inc.), phospho-
p44/42 MAPK (Thr202/Tyr204) and p44/42 ERK1/2 (Cell Signalling Technology, 
Inc.), FAK (GeneTex, Inc.), MEK-1 (EDM-Millipore), Actin α-Smooth Muscle (clone 
1A4; A2547; Sigma-Aldrich). The further peroxidase-secondary IgG incubation 
(1:2000 dilution) (Sigma-Aldrich) was performed at room temperature for 1,5 hours. 
Image acquisition and densitometric analysis were performed with Quantity One 
software on a ChemiDoc XRS instrument (BIO-RAD). All Western blots were 
repeated in at least 3 independent experiments. GAPDH or Actin were used as 
internal loading control to normalize protein expression. 
 RNA extraction, reverse transcription and quantitative real-time PCR. 
RNA extraction from H295R, ASCs and mature adipocytes, co-cultured or grown 
alone for 7 days, was performed using the RNeasy Mini Kit (Qiagen) according to 
the manufacturer's instructions. Briefly, pellets of cells, collected by trypsinization 
and centrifugation, were resuspended in RTL-1% β-mercaptoethanol buffer, added 
with 70% ethanol, column purified through sequential centrifugation steps and 
finally eluted in 50 µl RNase-free H2O. RNA concentration was assessed on a 
Nanodrop spectrophotometer (Thermo Fisher Scientific). For each RNA sample, 
cDNA was obtained by performing reverse transcription PCR starting from 250 ng 
RNA in 50 µl final volume reaction (Taqman RT-PCR kit; Applied Biosystems) using 
the following cycling conditions: 10 minutes at 25°C, 30 minutes at 48°C, 3 minutes 
at 95°C, hold 4°C. Further quantitative real-time PCR was carried out using primers 
and probes for the following genes: BMI-1, Nanog, OCT-4, Leptin, AdipoQ, FABP4, 
HSL, IL-8, IGF2, IGF1R, LepR, DPP4, CXCR7, CXCL12, IL-6, MCP-1, HSD11β1, 
GAPDH (Taqman Gene Expression Assay; Applied Biosystems). RT-PCR reactions, 
performed in triplicate for each gene, were carried out in 12,5 µl final volume on a 
ABI Prism 7900 Sequence Detector (Applied Biosystems) with the following cycling 
conditions: 15 seconds at 95°C plus 1 minute at 60°C for 40 cycles. The amount of 
target genes, normalized to the endogenous reference gene (GAPDH) and related to 
a calibrator (Stratagene), was calculated by 2-∆∆Ct.  
 Wound healing assay. H295R cultured alone or in co-culture with ASCs for 7 
days were trypsinized, seeded in a 12-well plate (1.5x106 cells/well) and grown up 
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to confluence. A sterile plastic 10 µl pipette tip was used to scratch the confluent 
cells monolayer in each well to generate a cell-free zone and, after a wash in PBS to 
eliminate the detached cells, fresh medium was added and cells were incubated for 
48h. In each well, migration was assessed under an inverted light microscope and 
quantified using a specific tool (MRI Wound Healing Tool) of the ImageJ software at 
designated time points, i.e. 0, 24 and 48 hours post-scratch. The percentage of 
migration rate was expressed as (1 −  residual area)/(initial area) × 100. 
 Invasion assay. The cell invasion assay was performed with a basement 
membrane-coated CytoSelectTM 24-well cell invasion assay kit (Cell Biolabs), 
according to the manufacturer's instructions. Briefly, H295R cells, previously 
cultured alone or co-cultured with ASCs for 7 days, were trypsinized and plated in 
the upper chamber of the invasion plate (3x105 cells/well) in serum free culture 
medium. Complete culture medium (DMEM/F12 plus 10% FBS) was added to the 
lower chamber. Cells were incubated for 48h at 37°C in 5% CO2 atmosphere. The 
non-invasive cells were then removed from the inside of the inserts, that were then 
transferred to a clean well containing a Cell Stain Solution and incubated for 10 min 
at room temperature. The inserts were washed in water, allowed to air dry and 
transferred to an empty well containing an Extraction Solution. After 10 min 
incubation on an orbital shaker, samples were transferred to a 96-well microtiter 
plate and the OD 560 nm was measured in a microplate reader (VICTOR multilabel 
plate reader; Perkin-Elmer). The OD 560 nm value related to the Extraction Solution 
alone was used as the background subtraction factor. The assay was repeated in 
three different co-culture experiments. 
 Immunofluorescence. H295R cells were seeded on glass coverslips in 6-well 
plates (105 cells/well) and cultured alone or together with ASCs grown in cell 
culture inserts (8×103cells/insert). After 7 days, H295R were fixed in 4% PFA, 
permeabilized in 0,2% PBS-Tryton and incubated with the ActinGreen™ 488 
ReadyProbes® Reagent (Thermo Fisher Scientific, Inc.) for 40 minutes to stain F-
actin cytoskeleton. Coverslips were then mounted on microscope slides in the 
presence of ProLong® Gold antifade reagent with DAPI (Life Technologies). 
Fluorescence was acquired with a Leica DM4000 epifluorescence microscope (Leica 
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Microsystems GmbH). Coverslips incubated with only 5% PBS-horse serum were 
used as negative controls. 
 ELISA assay. The conditioned medium related to ASCs cultured alone or 
together with H295R for 9 days was analyzed with an ELISA kit for the detection of 
human SDF-1a (CXCL12A) (Thermo Scientific™ Pierce™), according to the 
manufacturer's instructions. Briefly, samples were incubated in the assay plate 
containing the anti-SDF-1a antibody for 2,5 hours at room temperature. After 
washings, samples were incubated with the biotinylated antibody for 1 hour at 
room temperature. Subsequent streptavidin-reagent and TMB substrate  incubation 
were performed before measuring the OD 450/550 nm on a microplate reader 
(VICTOR multilabel plate reader; Perkin-Elmer). Each point was performed at least 
four times in at least three different experiments. Sample absorbance values were 
interpolated on a standard curve to obtain the relative concentrations. The assay 
sensitivity was 80 pg/ml. Each value was normalized on the relative cell number. 
 Statistical analysis. Statistical analysis was performed using SPSS 22.0 software 
(SPSS, Inc.). The Kolmogorov–Smirnov test was used to verify the normal 
distribution of data, expressed as mean ± SE. Student’s t test was applied for 
comparison of two classes of data. A P < 0,05 value was considered as statistically 
significant. 
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Results 
 
1) Cell proliferation and morphology of both H295R and ASCs are 
altered during co-culture 
An in vitro co-culture system was set up to assess the reciprocal influence of H295R 
adrenocortical cancer cells and human adipose-derived stem cell (ASCs) on cell 
behavior and characteristics. The use of specific 6-well inserts with a porous 
membrane allowed for culturing the two cell types in the same medium, avoiding 
direct cell contact but maintaining a constant exchange of soluble factors between 
the two compartments.  
First, H295R and ASCs were co-cultured up to 9 days and monitored at designated 
time points (0, 2, 3, 7, 9) to assess whether a variation in the proliferation rate was 
induced compared to the single cultures. Further gene and protein expression 
analysis was performed to investigated the possible intracellular pathways 
involved. Microscopy observation allowed to evaluate morphological variations. 
 H295R co-cultured with ASCs showed a significant increased in cell proliferation 
at day 9 co-culture, compared to H295R cultured alone, evaluated at the same time 
point (8.60 vs. 6.21-fold) (Fig. R2, A), indicating that a pro-proliferative signaling is 
triggered in the presence of ASCs. Western blot analysis was performed on protein 
samples extracted from H295R after 7 day mono- or co-culture in order to 
investigate whether the IGF-1R/MAPK signaling, which sustains the proliferative 
autocrine loop in adrenal cancer,  was involved in mediating such proliferation gain. 
Although the expression of the IGF1 receptor was not altered, a significant increase 
of MEK and p-ERK expression was observed, indicating an up-regulation of this 
intracellular  signaling when ASCs are present. Moreover, at the same time point, 
cells in co-culture showed a significant increase in glucose uptake (1.26-fold), 
measured by incorporation of 2-deoxy-[3H]D-glucose, thus indicating a higher 
metabolic activity of H295R stimulated by ASCs (Fig. R2, B, C). 
Under conventional light microscope observation, H295R co-cultured with ASCs 
appeared differently distributed on the well surface compared with H295R cultured 
alone: unlike the wide, foci-presenting clusters typically observed in our H295R 
cultures, cells formed smaller spaced clusters and acquired a well defined sharp 
shape (Fig. R3), thus suggesting a variation in cell-cell contact dynamics (Fig. R3).  
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Figure R2. The pro-proliferative effect of ASC co-culture on H295R. A) H295R alone (H295R) or co-
cultured with ASCs (H295R+ASC) were assessed for cell proliferation at the indicated time points (2, 3, 
6 and 9 days) by direct cell count. The proliferative rate was calculated as fold increased versus T0. 
Glucose uptake measurement (B) and Western Blot analysis of IGF-1R, MEK1, total ERK and pERK 
expression (C) were compared in cell samples derived from H295R after 7 day mono- or co-culture. For 
Western Blot analysis, GAPDH was used as internal loading control. Both protein expression and 
glucose up-take were calculated as fold increase versus H295R alone. Data are expressed as the mean ± 
SE in at least three independent experiments. * P < 0,05; ** P < 0,001, H295R+ASCs vs. H295R. 
Figure R3. H295R cultured with ASCs show a different distribution compared to the control.
Representative images of H295R cultured alone (A) or in the presence of ASCs (B). Original 
magnification: X10. 
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Transmission electron microscopy was also performed on ultrathin cell sections to 
evaluate H295R ultrastructure following the two culture conditions. The main 
difference was represented by a dramatic decrease of lipid droplets in H295R 
cultured in the presence of ASCs compared to H295R mono-colture (Fig. R4), thus 
indicating a possible increase in lipid metabolism. 
 
 
 
 Proliferative and morphological aspects were concomitantly evaluated in ASCs 
after mono- or co-culture in the setting of the same experiments described above for 
H295R. ASC proliferation was assessed at the same designated time points and a 
statistically significant increase in the proliferative rate was observed starting from 
day 6 co-culture (3.49 vs. 2.69-fold), with a significant difference at day 9 (10.12 vs. 
3.85-fold) (Fig. R5, A). Also for ASCs, glucose up-take was significantly increased in 
co-culture compared to control ASCs (2.06-fold) (Fig. R5, B), indicating that the 
presence of H295R induces ASCs to enhance glucose metabolism. Consistently, the 
insulin-independent glucose transporter GLUT-1 appeared up-regulated in ASCs 
co-cultured with H295R compared to ASCs alone, as assessed by Western Blot 
analysis (Fig. R5, B, inset). Due to their mesenchymal stem origin, ASCs express a 
set of specific markers, including Bmi-1, Nanog and Oct-4, which associate with the 
stem potential maintenance. Following co-culture, the expression of all the three 
stem genes was significantly decreased (2.8, 3.1 and 1.3-fold, respectively) compared 
to control ASCs, as assessed by Taqman assay (Fig. R5, C). This suggests that soluble 
factors secreted by tumor cells and exchanged within the co-culture system are able 
Figure R4. H295R ultrastructure modifications after co-culture. Representative images of control 
H295R (A) and H295R co-cultured for 7 days with ASCs (B) showing a considerable loss of lipid 
droplets (arrow). Scale bars = 5 µm. 
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to recruit and induce ASC increased proliferation as well as commitment toward 
adipose lineage, likely acquiring a phenotype metabolically more prone to sustain 
cancer cell growth. Consistently with this hypothesis, a considerable over-
expression of αlpha-Smooth Muscle Actin (α-SMA), a protein specifically 
indentifying myofibroblast-like cells, was detected by Western Blot analysis in 
protein samples extracted from ASCs cultured for 7 days with H295R compared to 
the control (Fig. R5, D).  
 
 
Figure R5. The presence of H295R prompts ASC proliferation and drives ASC differentiation 
toward a myofibroblast-like phenotype. A) ASCs alone (ASC) or co-cultured with H295R (ASC+ 
H295R) were assessed for cell proliferation at the indicated time points (2, 3, 6 and 9 days) by direct 
cell count. The proliferative rate was calculated as fold increased versus T0. Glucose uptake 
measurement and Western Blot analysis of GLUT-1, GLUT-4 and α-SMA expression (B, D) were 
compared in cell samples derived from ASCs after 7 day mono- or co-culture. For Western Blot 
analysis, GAPDH or Actin were used as internal loading control. Both protein and gene expression (C) 
were calculated as fold increase versus ASCs alone. Data are expressed as the mean ± SE in at least 
three independent experiments. * P < 0,05; ** P < 0,001, ASCs+H295R vs. ASCs. 
A macroscopic change 
ASCs co-cultured wi
densely distributed in
form cell bundles (Fig. R6). 
 
 
 
Transmission electron microscopy
allowed to appreciate several ultrastructure modifications 
the two conditions. ASCs cultured alone 
membrane organized in microvilli and 
bodies. Mitochondria 
typical transverse cristae. Rough endoplasmic reticulum was not of particular
extent, as well as Golgi
presumably endosomes or lysosome precursors
with H295R, instead, showed cytoplasmic structures typically associated with a 
metabolic active cell: rough endoplasmic reticulum was diffusely represented, with 
huge amount of ribosomes on its surface. Golgi
and lysosome-like 
presence of lipid droplets was observed. Interestingly, mitochondria were different 
in size and shape, becoming smaller and roundish (Fig. R7, C, D, E). Thus, the 
presence of cancer cell
expression and morphological features toward a phenotype more differentiated and 
metabolically active. 
Figure R6. ASCs cultured in the presence of H295R show a different gross morphology compared to 
the control. Representative images of ASCs cultured alon
Original magnification: X10.
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Figure R7. ASC ultrastructure shows substantial changes after co-culture. Representative images of 
ASCs cultured alone (A; zoom in: B) or in the presence of H295R (C; zoom in: D, E) for 7 days. 
Different fields with the same original magnification were digitally merged to reconstruct a wider 
cell portion. N=nucleus; M=mitochondria; RER=rough endoplasmic reticulum; Ly=lysosome; 
G=Golgi cisternae; L= lipid droplet. Scale bars = 2 µm (A, C) and 1 µm (B, D, E). 
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2) H295R cell migration and invasion ability is gained in the presence 
of ASCs 
Once ascertained that a reciprocal interaction is established between the two cell 
types in co-culture, we focused on cancer cell features in order to investigate 
whether the presence of ASCs could affect cancer cell motility and migration. H295R 
ability to heal an induced wound was assessed by wound healing assay after 7 day 
co-culture with ASCs. The percentage of migrating cells, evaluated at 24 and 48 
hour post-scratch, was significantly higher in H295R previously co-cultured with 
ASCs compared to the control (Fig. R8, A, B). Moreover, the same H295R stimulated 
by ASCs showed also a statistically significant higher capacity to migrate through a 
basement membrane compared to H295R cultured alone, as assessed by a specific 
invasion assay (Fig. R8, C).  
Figure R8. H295R migration and invasion ability is gained after ASC co-culture. A) Quantification 
of the scratched areas was carried out by using the ImageJ MRI-Wound Healing Tool and the 
percentage of migrating cell was calculated as following: (1 −  residual area)/(initial area) × 100. B) 
Representative images of wound healing assay at 0 and 48 hour post-scratch in H295R previously 
cultured alone or in the presence of ASCs for 7 days. Original magnification: X5. C) Invasion was 
assessed by specific a colorimetric assay and the invasion index was calculated as fold increase vs. 
H295R. Data are expressed as the mean ± SE in at least three independent experiments. * P < 0,05; ** 
P < 0,001, H295R+ASC vs. H295R. 
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We further performed Western blot assay to assess the expression of proteins 
associated with cell migration, particularly Focal Adhesion Kinase (FAK), RhoA and 
Fascin-1, which are involved in the formation of lamellipodia, filopodia and focal 
adhesion structures. H295R co-cultured with ASCs showed a statistically significant 
increased expression in all the three proteins compared to the control (Fig. R9, A). 
Also, we evaluated the actin cytoskeleton organization by performing 
immunofluorescent staining of F-actin: H295R cultured in the presence of ASCs 
showed an altered morphology compared to H295R cultured alone, acquiring a 
more elongated and polarized shape. Moreover, their cytoplasmic stress fibers 
appeared less defined and F-actin seemed to form focal structures rather than 
homogeneously distribute along the plasma membrane (Fig. R9, B). This suggests 
that a cytoskeletal re-organization supporting cancer cell migration is induced 
during co-culture. 
 
3) The presence of H295R impairs ASC ability to efficiently 
differentiate toward mature white adipocytes 
Focusing on the other cell compartment of our co-culture system, we evaluated the 
functional properties of ASCs when cultured in the presence of H295R compared to 
ASC mono-colture. As already mentioned, ASCs constitute the stem reservoir for 
the adipose tissue. Under appropriate stimulation, they are able to differentiate 
toward white adipocytes, with a substantial change in cell morphology, gene 
expression and adipokine secretion. To assess this property in our system, we 
cultured ASCs, alone or together with H295R, in the presence of a specific medium 
inducing adipogenic differentiation. After 10 days, we analyzed the expression of 
specific markers related to adipose functionality, such as Adiponectin (AdipoQ), 
FABP4 and Hormone Sensitive Lipase (HSL) genes: H295R co-culture drastically 
reduced the  expression of all the three genes in the obtained differentiated 
adipocytes, as showed by Taqman assay (Fig. R10, A). As adipocyte differentiation 
correlates with the amount of intracellular lipids stored in typical triglyceride 
droplets, we evaluated the lipid content in adipocytes induced to differentiate in the 
presence or not of H295R. Quantification of cell triglyceride content by AdipoRed 
assay showed that adipocytes obtained during H295R co-culture significantly  
Results 
86 
 
 
decreased their lipid content compared to the control (Fig. R10, B), thus indicating 
that the presence of cancer cells affects the ability of ASCs to efficiently differentiate 
toward mature adipocytes, which instead achieve an intermediate state between 
undifferentiated ASCs and mature adipocyte. Consistently, images of the same 
Figure R9. Expression of migration-related proteins and F-actin immunofluorescent staining in 
H295R after mono- or co-culture. A) Western blot analysis of FAK, RhoA and Fascin-1 were 
performed on cell lysates of H295R cultured alone (H295R) or together with ASCs (H295R+ASC) for 7 
days. Densitometric quantification of protein bands was carried out using GAPDH as internal loading 
control. Data are expressed as the mean ± SE in at least three independent experiments. * P < 0,05; ** P 
< 0,001. B) Representative images of immunofluorescence performed on H295R after mono- or co-
colture stained for the F-actin cytoskeleton (green). DAPI staining (blue) was used to visualize cell 
nuclei. Original magnification: X100; zoom in: X2. 
adipocytes acquired 
difference in lipid droplet size: 
with larger lipid droplets stuffing the entire cytoplasm
from ASCs co-cultured with H295R showed significan
(Fig. R10, C).  
 
 
However, the morphology of 
be consistent with that of brown adipocytes (see 
evidence in the literature that
browning may play an importan
Figure R10. The presence of H295R affects ASC ability to efficiently differentiate toward mature 
white adipocytes. A) Taqman assay was performed on cell samples from ASCs, used as ne
control, and adipocytes differentiated 
(ADIPO+H295R) for 10 days. Gene expression related to AdipoQ, FABP4 and HSL was calculated as 
fold increase vs. ASCs. AdipoQ
increase to the right one. B) Adipocyte lipid content, assessed by AdipoRed assay, was calculated as 
fold increase vs. ASC, whose value = 1 is indicated by the white dashed line. Data are expres
mean ± SE in at least three independent experiments. 
ADIPO. C) Representative images of AdipoRed
droplets (green) in samples from ASC (negative control),
counterstained with DAPI (blue). Original magnification: X20.
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Singh et al, 2016), one could speculate that a similar process could take place in our 
co-culture system. In support of this hypothesis, we found that adipocytes 
differentiated in vitro in the presence of H295R express the Uncoupling Protein 1 
(Ucp-1) gene compared to ASCs used as negative control (19.92 ± 5.04-fold; P < 
0.05). However, further analysis is needed to confirm such a differentiation shift 
from WAT to BAT characteristics. 
 
4) The potential molecular interaction underlying H295R/ASCs 
crosstalk 
As already described, our co-culture system allows the two cell types to interact 
thanks to the exchange of soluble molecules through the porous membrane 
separating the two compartments. Therefore, one of the main purposes was to 
investigate the factors produced and secreted by both ASCs and H295R potentially 
involved in their crosstalk.  
Metabolic adaptation is one of the key process occurring within the tumor 
microenvironment, with lactate playing a central role in mediating tumor/stroma 
cross-interaction and in sustaining tumor progression (see Introduction, chapter 3). 
Basing on the results obtained on cell proliferation during co-culture, we assessed 
the concentration of glucose and lactic acid in the conditioned media of cells co-
cultured or cultured alone for 72 hours, in order to evaluate whether a metabolic 
change toward aerobic glycolysis was occurring. In our in vitro reproduced 
microenvironment, we measured decreased glucose levels, accordingly with the 
previously observed increase of glucose up-take in both cell types; instead, lactic 
acid concentration significantly increased, particularly in the media related to co-
cultured ASCs (Tab. R1). This suggests on one hand that the H295R-induced higher 
proliferation in co-cultured ASCs may rely on a metabolic shift toward glycolysis; 
on the other one, that the augmented proliferation of H295R in co-culture could be 
fueled by lactate produced by ASCs and released into the medium. However, 
further investigation is needed to confirm the role of lactate in H295R/ASCs co-
culture system. 
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Other soluble factors specifically produced by ASCs or H295R, and involved in 
potentially prompting cell proliferation, were further investigated. Among all the 
adipokines produced by ASCs, leptin and interleukin-8 (IL-8) have been associated 
with increased cancer proliferation, migration and invasion (Delort et al, 2015; Wang 
et al, 2015; Cao et al, 2016). Accordingly, gene expression analysis of cell samples 
from ASCs co-cultured with H295R for 7 days revealed a statistically significant 
increment of both leptin and IL-8, a cytokine involved in upregulation of leptin 
production, compared to the control (Fig. R11, A). A concomitant increase of leptin 
receptor (Ob-R) gene expression was observed in H295R in the same co-culture 
setting compared to H295R cultured alone (Fig. R11, B). Moreover, the same H295R 
in co-culture showed a decreased expression of both IGF2 and its receptor, IGF-1R 
(Fig. R11, B). Thus, the Leptin/Ob-R signaling may underlie the increased 
proliferation of cancer cells in our system, indeed activating a pro-proliferative 
pathway alternative to the IGF2 paracrine-autocrine loop typically up-regulated in 
adrenocortical carcinoma (Cantini et al, 2008). 
To elucidate the molecular mechanisms underlying the higher motility/migratory 
ability of H295R when co-cultured in the presence of ASCs, we investigated the 
SDF-1 (CXCL12)/CXCR4/CXCR7 axis in our system, since it is one of the main 
activated pathways within the TME, sustaining tumor proliferation, migration and 
invasion (see Introduction, chapter 3). We assessed the level of gene and protein 
expression of the chemokine SDF-1, as well as its secretion, in ASCs co-cultured 
with H295R for 7 days compared to the control: differently from what expected, 
SDF-1 gene expression was decreased after co-culture (Fig. R12, A), as well as 
protein expression (Fig. R12, B). 
Table R1. Glucose and lactic acid content in conditioned media from mono- and co-cultures. 
Immuno-enzymatic assay was performed to meseaure glucose and lactic acid concentration in 
conditioned media from both ASCs and H295R cultured alone or in co-culture. The absolute 
concentration was normalized on the relative cell number and expressed as fold increase vs. the mono-
colture. * P < 0.05, co-culture vs. mono-culture condition. 
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Figure R11. Potential molecular crosstalk underlying cancer cell proliferation. A) Leptin and IL-8 
gene expression was assessed by Taqman assay in cell samples derived from 7 day ASC mono- (ASC) 
or co-culture (ASC+H295R). The relative expression level was calculated as fold increase vs. ASC. B) 
Gene expression of Ob-R, IGF2 and IGF-1R in H295R cultured alone (H295R) or together with ASCs 
(H295r+ASC) for 7 days, was calculated as fold increase vs. H295R. Data are expressed as the mean ± 
SE in least three independent experiments. * P < 0.05; ** P < 0.001, co-culture vs. mono-culture. 
 
However, when assessed in the conditioned media, the levels of the secreted SDF-1 
were significantly higher in ASCs co-cultured compared to ASCs cultured alone 
(Fig. R12, C). Thus, we hypothesized that, in the setting of the co-culture, high 
amount of secreted SDF-1 induce a negative loop inhibiting the further production 
of SDF-1 by ASCs. In addition, we observed a concomitant decreased gene 
expression of the Dipeptidyl Peptidase 4 (DPP4), a peptidase able to degrade 
multiple chemokines, including SDF-1. Therefore, lower levels of DPP4 could assure 
a higher availability of SDF-1, thus concurring to the negative regulation of this 
chemokine production. On the other hand, we assessed the expression of the SDF-1 
receptors, namely CXCR4 and CXCR7, in H295R co-cultured or not with ASCs: after 
7 day co-culture, H295R decreased CXCR4 expression, while increased CXCR7 
expression. Thus, in our system a shift between CXCR4 and CXCR7 expression 
occurs, being the axis activation likely mediated  CXCR7-downstream pathways. 
Finally, we investigated the presence of factors potentially involved in the 
immunomodulatory mechanisms that have widely been described to occur 
following the crosstalk between tumor cells and their stromal microenvironment, 
contributing to tumor progression. Interleukin- 6 (IL-6) and Monocyte 
Chemoattractant Protein-1 (MCP-1) are two of the main inflammatory cytokines 
produces by ASCs. We assessed the expression of both IL-6 and MCP-1 genes in 
ASCs co-cultured with H295R for 7 days, observing a significant decrease compared 
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to control ASCs (Fig. R13, A). This suggests that adrenocortical cancer cells may be 
able to achieve immune-tolerance by affecting adipose inflammatory cytokine 
production. Another mechanism could be linked to increased levels of cortisol 
production: in fact, this glucocorticoid is specifically produced by adrenocortical 
cells and exerts anti-inflammatory effects. Accordingly, we detected higher level of 
cortisol in the conditioned media of to H295R co-cultured with ASCs compared to 
the control. Concomitantly, an increased expression of the Hydroxysteroid 11-beta 
Dehydrogenase type 2 (HSD11B2) gene, encoding for the enzyme that converts 
cortisol to cortisone, was detected in co-cultured H295R compared to the mono-
culture (Fig. R13, B). Interestingly, HSD11B2 expression was even higher when 
H295R were co-cultured with ASCs induced to differentiate toward mature 
adipocytes, i.e. a mixed culture consisting of both undifferentiated ASCs and pre-
adipocytes. 
 
 
 
 
 
 
Figure R12. SDF-1/CXCR4/CXCR7 axis in H295R/ASCs co-culture. Gene expression related to SDF-1, 
and DPP4 (A) and CXCR4 and CXCR7 (D) genes was assessed by Taqman assay in ASCs and H295R 
respectively, after 7 day co-culture compared to the single culture. Expression levels were calculated as 
fold increase vs. the relative controls. B) Western blot analysis of SDF-1 in ASCs co-cultured compared 
to the control. GADPH was used as internal loading control. C) Extracellular levels of SDF-1 measured 
by ELISA assay in the conditioned media of ASCs after 7 day mono- or co-culture. The absolute 
concentrations were normalized on the relative cell number and expressed as fold increase vs. ASC. 
Data are expressed as the mean ± SE in least three independent experiments. * P < 0.05; ** P <0.001, co-
culture vs. mono-culture. 
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Figure R13. Factors potentially involved in immunomodulatory mechanisms in co-culture. Gene 
expression related to IL-6, and MCP-1 (A) and HSD11B2 (B, lower panel) genes was assessed by 
Taqman assay in ASCs and H295R respectively, after 7 day co-culture compared to the single culture. 
Expression levels were calculated as fold increase vs. the relative controls. C) Extracellular levels of 
cortisol measured in the conditioned media of H295R after 7 day mono- or co-culture. The absolute 
concentrations were normalized on the relative cell number and expressed as fold increase vs. H295R. 
Data are expressed as the mean ± SE in least three independent experiments. * P < 0.05; ** P <0.001, co-
culture vs. mono-culture. 
 
5) A reciprocal interaction is established also between H295R and "in 
vitro" differentiated adipocytes 
Taking together, all findings described above illustrate that, during co-culture, 
H295R are able to induce significant morphological and functional alterations in 
ASCs, which in turn concur to increase cancer cell proliferation and invasiveness. 
Since a physiological adipose microenvironment would consist of mature 
adipocytes with their stem pool of ASCs, we decided to investigate whether co-
culturing H295R with in vitro differentiated adipocytes induced some effects on the 
two cell compartments. At this purpose, we induced ASCs to differentiate for 7 days 
in the presence of the appropriate adipogenic medium, keeping culturing the 
obtained pre-adipocytes in the presence of H295R for additional 9 days. First, we 
evaluated the proliferative rate of H295R co-cultured with adipocytes compared to 
the control: even if we observed only a slight non statistically significant increase in 
cell proliferation in co-cultured H295R compared to the control (5.01 ± 0.28 vs. 4.68 ± 
0.86-fold), Western Blot analysis revealed a higher expression of MEK and p-ERK 
(Fig. R14, left panel), indicating that MAPK-mediated pathway is enhanced by the 
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presence of adipocytes. Moreover, the expression of the migration-related proteins 
FAK, RhoA and Fascin-1 was also increased (Fig. R14, right panel), suggesting that 
also mature adipocytes contribute to cancer cell migration/invasiveness.  
 
 
Figure R14. Expression of proliferation- and migration-related proteins in H295R co-cultured with 
mature adipocytes. Protein expression related to MEK, p-ERK, FAK, RhoA and Fascin-1 was assessed 
by Western blot analysis in cell samples from H295R co-cultured for 9 days with previously in vitro 
differentiated adipocytes (H295R+mADIPO) compared to the control (H295R). Bar charts represent 
protein expression quantified by densitometric analysis of protein bands normalized on GAPDH, used 
as internal loading control, and calculated as fold increase vs. H295R. Data are expressed as the mean ± 
SE in at least three independent experiments. * P < 0,05; ** P < 0,001, co-culture vs. mono-culture. 
 
We further evaluated the effect of H295R on adipocyte functionality: by assessing 
Adiponectin (AdipoQ) and FABP4 gene expression, we observed a statistically 
significant decrease in the expression of both genes in adipocytes co-cultured with 
H295R compared to adipocytes cultured alone (Fig. R15, A). This was accompanied 
by a significant decrease in lipid content, quantified by AdipoRed assay and 
confirmed by the observational analysis of adipocyte lipid droplets by 
epifluorescence microscopy (Fig. R15, B, C). Such a decrease in the lipid content in 
adipocytes interacting with cancer cells is consistent with the widely described 
delipidation process occurring within the tumor microenvironment. Also, 
accordingly to what observed in the literature, adipocytes co-cultured with H295R 
expressed significantly higher levels of leptin compared to the control (4.50 ± 0.3-
fold; P < 0.001). 
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Figure R15. The presence of H295R affects the functionality of mature adipocytes. A) Taqman assay 
was performed on cell samples from ASCs, used as negative control, and in vitro differentiated 
adipocytes cultured alone (mADIPO) or co-cultured with H295R (mADIPO+H295R) for 9 days. Gene 
expression related to AdipoQ and FABP4 is expressed as fold increase vs. ASCs. B) Adipocyte lipid 
content, assessed by AdipoRed assay, was calculated as fold increase vs. ASC, whose value = 1 is 
indicated by the white dashed line. Data are expressed as the mean ± SE in at least three independent 
experiments. * P < 0,05; ** P < 0,001, co-colture vs. mono-colture. C) Representative images of 
AdipoRed-related fluorescence, staining intracellular lipid droplets (green) in samples from ASC 
(negative control), mADIPO and mADIPO+H295R. Cell nuclei were counterstained with DAPI (blue). 
Original magnification: X40. 
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Discussion 
In the complex setting of a cancer mass, several metabolic and molecular 
interactions are continuously established within the tumor microenvironment 
(TME) between cancer cell and the surrounding stroma, consisting of both different 
cell types and extracellular matrix components. Such a dynamic crosstalk leads to 
substantial modification in both cancer and stromal cell behavior, eventually 
supporting tumor growth and progression. The role of adipocytes and adipose 
progenitors as active players within this dynamic crosstalk has been demonstrated 
for many types of malignancy, with particular implication for tumor initiation and 
growth, as well as for local invasion and metastasis (Duong et al, 2017). Studying 
such interactions would help in elucidating canceralso the biology of adrenocortical 
carcinoma: in fact, adrenal glands present a substantial component of adipose tissue, 
thus the cross-talk with the surrounding adipose microenvironment may play a 
pivotal role in adrenocortical tumorigenesis and ACC progression. Unraveling the 
metabolic and molecular dynamics occurring within the ACC TME would allow to 
develop new therapeutic strategies addressing the specific cancer cells-
microenvironment crosstalk. 
In this study we reproduced a simplified in vitro tumor microenvironment by co-
culturing the adrenocortical tumor cells H295R with cells of adipose lineage, both 
adipose-derived stem cells (ASCs) and in vitro differentiated adipocytes, in order to 
evaluate the paracrine effects of the adipose component on H295R cell behavior, as 
well as the influence of H295R cells on the adipose compartment. The co-culture 
system we employed, consisting of specific 6-well inserts with a porous membrane, 
was particular helpful to address our aim, since it allowed to maintain physically 
separated the two cell types, concomitantly permitting the exchange of soluble 
factors between the two compartments. Thus, in the setting of the same 
experiments, we assessed different features in the two cell compartments at the 
same time. 
First investigating the co-culture effect on cancer cells, we evaluated the H295R 
proliferation in the presence an adipose microenvironment, meaning ASCs or 
mature adipocytes, compared to H295R mono-culture, demonstrating that cancer 
cells enhance their proliferation rate when co-cultured with adipose cells. This 
increase can be likely mediated by the up-regulation of the MAPK intracellular 
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signaling, as supported by the observed protein over-expression of MEK and p-
ERK. Beyond this effect on cell proliferation, we demonstrated that the presence of 
adipose cells trigger H295R migration and invasiveness, as shown by both wound 
healing and invasion assays, as well as by the increased expression of migration-
related proteins, particularly Focal adhesion kinase (FAK), RhoA and Fascin1. These 
three proteins are involved in the cytoskeletal re-organization underlying cell 
motility, inducing the formation of specialized structures, such as focal adhesion, 
lamellipodia and filopodia. A variation in cell-cell interactions and the stimulation 
of cytoskeleton re-organization was indeed evident in H295R stimulated by the 
presence of ASCs. Notably, the three proteins have been found over-expressed in a 
variety of human tumors, associating with cancer aggressiveness. Particularly, FAK 
seems to play a crucial role in the TME, promoting tumor progression and 
metastasis through effects on both cancer and stromal cells: this is a cytoplasmic 
protein tyrosine kinase that exerts multiple functions controlling cell movement, 
invasion, survival, gene expression related to the epithelial-to-mesenchymal 
transition (EMT), and cancer stem cell self-renewal (Sulzmaier et al, 2014). RhoA is 
part of the Rho GTPases family, an ubiquitously expressed division of GTP-binding 
proteins involved in the regulation of cytoskeletal dynamics and intracellular 
signaling, whose abnormal expression and activation have major consequences for 
cancer progression and metastasis (Jansen et al, 2017). Finally, Fascin-1, a 
filamentous actin-binding protein, is a crucial in organization and functionality of 
cell protrusions for cell migration, and has been proposed as a prognostic biomarkes 
in several cancer types (Adams, 2015; Min et al, 2015; El-Balat et al, 2016). Notalby, it 
has been demonstrated to be a potential biomarker in adrenocortical carcinoma (Poli 
et al, 2015). Therefore, in our co-culture system Fascin -1 up-regulation becomes 
particularly meaningful.  
 If on one hand we were interested in exploring how the adipose 
microenvironment may sustain cancer cell aggressiveness, on the other one we also 
wanted to evaluate the alterations induced by cancer cells on both ASCs and mature 
adipocytes as part of their crosstalk. The main finding observed was that H295R are 
able to actively "recruit" ASCs, affecting their morphology and functionality and 
driving their differentiation toward a phenotype more prone to sustain tumor 
growth and progression. Accordingly to what demonstrated in other cancer types 
(Jeon et al, 2010; Jotzu et al, 2010; Cho et al, 2011, 2012; Do et al, 2012; Park et al, 2013), 
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H295R-stimulated ASCs enhanced their proliferation and acquired a myofibroblast-
like phenotype, concomitantly decreasing their stem markers. Accordingly, 
morphologic alterations were clearly observed in ASCs after co-culture with H295R. 
Moreover, when induced to differentiate in the presence of cancer cells, ASCs ability 
to give rise to mature adipocytes was impaired. Instead, they achieved an 
intermediate state between undifferentiated ASCs and mature adipocytes, which 
probably serves more efficiently to cancer cell sustaining. As alternative hypothesis, 
it may be possible that ASC differentiation is shifted by cancer cells toward 
browning, since we observed the expression of the brown adipocyte-specific 
Uncupling Protein-1 (UCP-1) gene in adipocytes differentiated in the presence of 
H295R. This may be consistent with evidence indicating the potential occurrence of 
white adipose tissue browning in cancer, particularly related to cancer-associated 
cachexia: brown adipocytes, in fact, are responsible for thermogenesis, that has been 
hypotesized to underlie energy wasting and fat and muscle atrophy (Kir et al, 2014; 
Petruzzelli et al, 2014; Singh et al, 2016).  
The ability of cancer cells of altering the adipose microenvironment was further 
confirmed by co-culturing H295R and in vitro differentiated adipocytes, which 
showed a decreased functionality, measured in terms of decreased expression of 
specific adipogenic markers (i.e. Adiponectin and Fatty Acid Binding Protein 4 -
FABP4 - genes), as well as a loss of intracellular lipid content. This could indicate a 
lipolytic process induced by cancer cells and the release of free-fatty acids (FFAs), as 
widely described in other cancer types (Dirat et al, 2011; Nieman et al, 2011, 2013; 
Park et al, 2014; Balaban et al, 2017; Wang et al, 2017; Wen et al, 2017). FFAs, in fact, 
represents the main energy source provided by adipocytes within the TME to fuel 
cancer cells. Alternatively, the decreased expression of Adiponectin and FABP4, 
could be interpreted as an induced de-differentiation of adipocytes toward a more 
plastic and metabolically active cells, such as the fibroblast-like adipocyte-derived 
cells described in other types of cancer (Chirumbolo & Bjørklund, 2016; Zoico et al, 
2016).  
Metabolic adaptation represents one of the key process allowing tumor cell 
survival and proliferation. Lactate, produced at high levels in the TME following the 
reverse Warburg effect (Pavlides et al, 2009; Chiarugi & Cirri, 2016), has been 
described as one of the major players mediating tumor/stroma cross-interaction and 
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sustaining tumor progression. Alterations in glucose and lactic acid concentration 
were observed in the extracellular compartment of our co-culture system: 
consistently with a possible metabolic shift toward aerobic glycolysis, glucose level 
decreased in the conditioned media of both H295R and ASCs, with a concomitant 
increase of glucose up-take by cells, whereas lactic acid concentration was higher, 
particularly when measured in the media related to ASCs. Thus, lactate may 
represent a key factor in mediating cell proliferation in a complex intercellular 
interaction, in which ASCs recruited by H295R increase glycolysis, producing 
lactate which, in turn, can fuel cancer cell metabolism.  
Since our co-culture system actually allows a "soluble" interaction between the 
two cell compartments, the secreted factors released into the extracellular media are 
the obvious mediators of the observed effects. Adipose cells produce a variety of 
hormones, growth factors, chemokines, and adipokines, that play a critical role in 
modulating tumor microenvironment. Among them, leptin appears to be strongly 
involved in carcinogenesis and cancer metastasis, promoting cell proliferation and 
invasion, as well as angiogenesis (Duong et al, 2017). Leptin over-expression was 
observed in both ASCs and mature adipocytes co-cultured with H295R, which in 
turn up-regulated the expression of leptin receptor. This could explain the IGF-1R-
independent up-regulation of the MAPK signaling observed in H295R co-cultured 
with ASCs, together with the decreased level of IGF2 gene expression: leptin may 
trigger a pro-proliferative pathway alternative to the IGF2 paracrine-autocrine loop 
typically up-regulated in adrenocortical carcinoma (Cantini et al, 2008).  
Another pathway that seems to be involved in the crosstalk between 
adrenocortical cancer cells and the adipose microenvironment is represented by the 
CXCL12 (SDF-1)/CXCR4/CXCR7 axis, which has been shown to affect tumor 
progression by an autocrine/paracrine control of cancer cell survival, proliferation 
and migration (Guo et al, 2016). In our system, along with an increased 
concentration of SDF-1 measured in the conditioned media of co-cultured ASCs, we 
observed a de-regulation of CXCR4 and up-regulation of CXCR7 in co-cultured 
H295R. This is accordant with several evidence showing  CXCR7 over-expression in 
a variety of cancers (Hattermann et al, 2010; Deutsh et al, 2013; Hu et al, 2014; Lin et 
al, 2014; Wu et al, 2015; Shi et al, 2017) and a role for CXCR7 in negatively regulating 
CXCR4 (Uto-Konomi et al, 2013). Interstingly, in a mouse model of metastatic 
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neuroblastoma, CXCR7 has been shown to specifically mediate cells cancer homing 
to the adrenal glands (Mühlethaler-Mottet et al, 2015). Also, CXCR7 seems to be 
specifically required for transendothelial migration (Mazzinghi et al, 2008), 
mediating cancer cell interaction with the endothelia. 
To further investigate tumor adaptation within the TME, we also considered the 
immunomodulatory mechanisms possibly activated by the cross-interaction 
between H295R and adipose cells. The expression of genes encoding two of the 
main adipose inflammatory cytokines, Interleukin- 6 (IL-6) and Monocyte 
Chemoattractant Protein-1 (MCP-1), was decreased in ASCs after co-culture with 
H295R, thus suggesting that adrenocortical cancer cells may be able to achieve 
immune-tolerance through the modulation of cytokine production by adipose cells. 
In fact, lowering IL-6 levels could allow to mild the mobilization of anti-tumor T-
cells (Fisher et al, 2014), while low levels of MCP-1 have been associated to modest 
monocyte infiltration, resulting in tumor formation (Nesbit et al, 2001). The 
increased cortisol production and the up-regulation of its metabolizing enzyme 
(Hydroxysteroid 11-beta Dehydrogenase type 2 - HSD11B2) that we observed in co-
cultured H295R, may also concur to establish a low-level inflammation in the TME, 
supporting tumor progression. Some evidence, in fact, indicates that high levels of 
cortisol and HSD11B2 promote tumorigenesis and mediate immunomodulation in 
other types of cancer (Sidler et al, 2011; Voisin et al, 2017;Wu et al, 2017).  
In conclusion, our findings demonstrate that an active metabolic and functional 
crosstalk is established between adrenocortical cancer cell and cells from the 
adipose lineage. However, as an in vitro experimental model, our co-culture system 
present some limitations, fist of all represented by the pore size (0.4 µm diameter) of 
the insert membrane, which allows soluble factors and exosomes to pass from a 
compartment to the other, but likely prevents the exchange of larger secreted 
vesicles. Some type of experiments required H295R to be cultured inside the inserts 
thus, considering their small dimensions, larger pores should be avoid not to risk 
cell migration through the membrane. An alternative method to study the effect of 
secreted factors on cell behavior would be the use of conditioned media of one cell 
type directly in the mono-culture of the other. However, in this case the possibility 
to follow a dynamic intercellular crosstalk would be loss. Another point is 
represented by the cell models of adrenocortical carcinoma and adipose 
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microenvironment employed: H295R are not effectively reproducing the specific 
characteristic of ACC, whereas ASCs are derived from different individuals and 
would show variations in their functionality and differentiation ability. However, 
even being a simplified model of tumor microenvironment, our models allows to 
detect substantial modification in the two different compartments, pointing out the 
potential role of the surrounding adipose microenvironment in sustaining 
adrenocortical tumorigenesis and cancer progression. 
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PART II - Detection and characterization of circulating tumor 
cells in adrenocortical carcinoma 
 
Materials and methods 
 Patients and samples. Fourteen patients evaluated at our University Hospital 
for adrenocortical carcinomas who underwent surgery and are currently under 
follow-up were enrolled for this study, which was approved by the Local Ethical 
Committee. All patients agreed by written informed consent. Blood samples were 
collected in K2-EDTA tubes during standard blood draws, kept at 4°C and 
processed within 3 hours. For most of the patients, samples related to different time 
points were collected. 
 Blood filtration and CTC isolation. Blood samples were processed by using 
two different ScreenCell® filtration devices for CTC isolation, namely ScreenCell 
Cyto and MB kits, allowing for cytomorphological analysis and DNA extraction 
respectively. The filtration was performed according to the manufacturer’s 
instructions. Briefly, with the Cyto kit, 3 ml of blood were diluted in a specific 
dilution buffer for red blood cell lysis and cell fixing. A total volume of 7 ml of  
diluted blood was transferred into the filtration unit and filtered through the 
microporous filter, adding 1,6 ml PBS in order to remove red blood cell debris. At 
the end of the filtration process, each track-etched microfilter was released from the 
filtration module, placed on absorbing paper and washed with PBS, allowed to air 
dry and further stored at 4°C. For each patient, the blood sample was filtered in 
duplicate, while a third parallel filtration was performed by using the ScreenCell® 
MB kit: 6 ml blood, diluted with 1 ml of specific dilution buffer, were filtered as 
described above. The filter was finally released in the provided Eppendorf tube and 
stored at -20°C (Fig. R16). 
  CTC identification
was used to perform cytological studies, including hematoxylin/eosin staining and 
immunocytochemistry. Each filter was incubated with Hematoxylin S (Merck 
KGaA) for 2 minutes at 
with Shandon Eosin Y (Thermo Fisher Scientific) for 1 minute. Excess of eosin  was 
removed with distilled water and the filter was allowed to air dry, placed on a 
standard microscopy glass slide and
(DAKO) and 7 mm circular cover slip. CTCs were identified and enumerated under 
light microscope according to the following morphological criteria: cell size 
nucleo-cytoplasmic ratio 
basophilic cytoplasm.
was performed as following: filters were hydrated with Tris
pH 7.4) and incubated with permeabilizing buffer (TBS
minutes at room temperature. H
incubating filters in a bath 
20 minutes. Each filter was incubated overnight with 70 µ
human SF-1 (Upstate; dilution 1:50 in TBS
immersed in distilled water. Staining was achieved by treating each spot with 70 µl 
EnVision Detection System Perox
minutes at room temperature, followed by chromogen 3.3' diaminobenzidine 
Figure R16. Schematic representation of the 
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, enumeration and characterization. Track
room temperature, washed in distilled water and incubated 
 mounted with Faramount mounting medium 
≥ 50%, irregular nuclear shape, hyperchromatic nucleus, 
 To confirm cell adrenocortex origin, immunocytochemistry 
-buffered saline (TBS; 
-0,2% Triton 100X) for 5 
eat-induced epitope retrieval was performed by 
with Target Retrieval Solution (pH 9.0) (Dako) 
l monoclonal mouse anti
-1% BSA), washed with TBS 
idase/DAB, Rabbit/Mouse (K5007; Dako) for 40 
described CTC isolation workflow. 
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-etched filters 
≥ 16 µm, 
at 99°C for 
-
and 
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(Dako) for 10 minutes at room temperature. Filters were rinsed with water and 
nuclei were counterstained with Hematoxylin S. 
 Genomic DNA purification from CTCs and whole genome 
amplification. CTCs isolated with ScreenCell MB kit were processed according to 
the manufacturer’s protocol for DNA extraction, purification and amplification: 
filters were incubated with an appropriate lysis buffer at 56°C for 10 minutes and 
centrifuged 1 minute at 12000 g. The DNA within the flow-through was column 
purified through sequential centrifugation steps and finally eluted in 23 µl AE 
buffer (QIAamp DNA Micro Kit; Qiagen). Whole genome amplification was 
performed by using the GenomePlex® Single Cell Whole Genome Amplification kit 
(Sigma-Aldrich): DNA was fragmented by 1 hour incubation at 50 °C with an 
appropriate working solution, followed by 4 minutes at 99°C, and used for library 
preparation. Further amplification was performed in a final volume of 75µl mix in a 
thermal cycler as following: initial denaturation at 95°C for 3 minutes, 30 seconds at 
94°C plus 5 minutes at 65°C for 25 cycle, hold at 4°C. Negative and positive controls 
were amplified along with samples. 
 Targeted NGS sequencing. Tumor DNA from patients previously assessed 
for mutations was sequenced by NGS on a Ion PGM system (Thermo Fisher 
Scientific) with a targeted panel designed with the Ion AmpliSeq Designer tool 
(Thermo Fisher Scientific) and including 9 genes described as mutated in ACC 
(ZNRF3, TP53, CTNNB1, CDKN2A, MEN1, RB1, CDK4, GNAS, PRKACA) and a 
selection of 173 heterozygous SNPs distributed along chromosome arms associated 
with LOH in ACC. Libraries were prepared according to the Ion AmpliSeq protocol: 
the selected genes and SNPs were amplified by two multiplex PCR using 2 pools of 
primer pairs (355 total) in order to obtain amplicons with an average size of 150 bp. 
100 ng genomic DNA were used for each PCR reaction. Libraries were further 
amplified, purified and sequenced by semiconductor sequencing technology (Ion 
Torrent, Thermo Fisher Scientific). Vcf files were annotated with Annovar. Data 
were analyzed by using the RStudio software. 
 Digital-droplet PCR (ddPCR). The QX200 droplet digital PCRsystem (Bio-
Rad) was used for mutant detection in selected tumor and CTC DNA samples 
according to the manufacturer’s instructions. Two primer and probe pairs were 
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designed to amplify and target specific wild type and mutated sequences within the 
genes ZNRF3 (forward primer: 5'-CCGGTTTCACAGGAAGTG; reverse primer: 5' 
GACTCTTCAGCAATGGCTAA; wt probe: 5'-TGCAGCACCACAC, HEX-
conjugated; mut probe: 5'- TGCAGCAACACACCT, FAM-conjugated) and TP53 
(forward primer: 5'-GAGTCTTCCAGTGTGATG; reverse primer: 5'-
CACCATCCACTACAACTAC; wt probe: 5'-TCATGCCGCCC HEX-conjugated; mut 
probe: 5-TCATG+C+T+G+CCCA FAM-conjugated) (Eurogentec). ddPCR reactions 
were performed in 20 µl mix using 18 ng DNA with the following cycling 
conditions: 10 minutes at 95°C, 30 seconds at 94°C plus 1 minute at 57°C for 40 
cycles; 10 minutes at 98°C, hold at 4°C. Mutant and wild type allele concentration 
(copies/µl; CMUT and CWT, respectively) were determined basing of the number 
of positive and negative droplet for each fluorophore in each sample and mutant 
allele frequency (MAF) was calculated as following: MAF =CMUT/(CMUT +CWT). 
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Results 
 
1) CTCs can be detected in the peripheral blood of ACC patients with 
different clinical features 
We collected blood samples from 14 patients diagnosed for adrenocortical 
carcinoma, who underwent surgery and are currently under follow-up. Our cohort 
includes patients with different features related to disease presentation (tumor size, 
Weiss score, Ki67, stage), outcome (tumor recurrence or metastasis) and post-
surgical treatment, as summarized in Tab. R2. For some of the patients, the 
mutational profile of the primary tumor was also available, since they were 
analyzed in the setting of an European cohort for the study of the genomic 
landscape of ACC (Assié et al, 2014). Where present, gene mutations and 
homozygous deletions are indicated.  
For most of the patients, we performed blood draw at different time points, in order 
to have multiple samples over time. Blood was filtered to isolate circulating tumor 
cells (CTCs) by using the ScreenCell filtration devices, as described in the section 
above (see Materials and methods), and the circular microfilters were analyzed for 
CTC detection and characterization. Following hematoxylin/eosin staining, filters 
were assessed for CTC identification using the described cytomorphometric 
parameters. In our samples, we detected both single CTCs and CTC clusters, namely 
circulating tumor microemboli (CTM), considering morphometric parameters such 
as size (> 16 µm), irregular and hypercromatic nuclei and high nucleocytoplasmic 
ratio (Fig. R17, A, B, C). In some samples we also detected the so-called cancer-
associated macrophages-like cells (CAML), characterized by large size, multilobular 
or multiple nuclei and voluminous cytoplasm (Fig. R17, D). The relative number of 
CTC, CTM and CAML detected for each sample of each patient is indicated in Tab. 
R2. Further immunocytochemistry analysis was performed to assess the 
adrenocortical origin of the detected CTCs: a nuclear positivity for the Steroidogenic 
Factor-1 (SF-1) was observed, indicating the adrenocortical nature of cells, as also 
confirmed by comparing the SF-1 immunohistochemistry performed on tissue 
samples from the primary tumor of the same patients (Fig. R18). Thus, CTCs can be 
detected in the peripheral blood of ACC patients, even years after surgical resection 
of the primary tumor. 
  
Table R2. Characteristics of ACC patients analyzed for CTC detection and characterization. 
available; — = none. 
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na = not  
  
 
 
2) Experimental design for 
CTCs: preliminary results
The principal aim of
characterize at the molecular level the isolated CTCs, in order to compare their 
genetic profile with the primary tumor
evolution and progression in the 
of CTC isolation and DNA extraction and amplification, aimed to obtain a sufficient 
amount of DNA feasible for further downstream applications, in particular targeted 
NGS and digital-droplet PCR (ddPCR) (Fig. R19)
CTC DNA for the presence of 
primary tumor of the same patients, and to eventually obtain a single cell genetic 
profile to be compared to that of the primary tumor.
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 this study was to set up an experimental workflow to 
, thus eventually allowing to follow ACC 
single patient. This workflow includes a first step 
. The purpose 
single point mutations already detected in the 
 
Figure R17. 
images of hematoxylin/eosin 
staining of
C) and CAML (D), detected in 
the blood samples of ACC 
patients. Original magnification. 
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Figure R18. 
images of nuclear SF
performed on primary tumor 
samples (A) and on isolated 
CTCs (B) in the same patient.
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We started from patients whose tumor samples were already analyzed by NGS 
assay and SNP array (as part of European cohort for the study of the genomic 
landscape of ACC; Assié et al, 2014), in order to detect the presence of mutations and 
chromosome alterations (i.e. loss of heterozygosity, LOH ). In particular, we selected 
two patients showing mutations in ZNRF3 and TP53 genes, respectively (see Table 
R2, patient 2 and patient 13). Notably, these two genes have been described among 
the most frequently altered genes in ACC (Assié et al, 2014; Juhlin et al, 2015; Zheng 
et al, 2016). We used a dedicated ScreenCell filtration device to isolate CTCs and 
extract DNA. Further whole genome amplification was performed to increase the 
amount of DNA. We designed a specific ddPCR assay for each gene in order to 
target the specific mutation in each patient, and we tested the assays on the relative 
DNA tumor samples. We were able to detect the mutated allele in both patients (Fig. 
R20, A), thus we could confirm the specificity of our assays. Notably, the allelic 
frequency of the mutations detected by ddPCR was comparable to that obtained 
with the previous NGS assay (Fig. R20, B). On the contrary, the results of ddPCR 
performed on CTC DNA from the same patients were disappointing: no signal was 
detected in any of the samples, even related to the wild type alleles (Fig. R20, C). 
Since our CTC isolation system does not allow to obtain a pure sample of CTC, but 
other blood cells, including lymphocytes, still remain after filtration, at least we 
should detect germline DNA in our samples. Thus, some technical issue related to 
CTC DNA purification and amplification affects our system and needs to be 
investigated. 
Figure R19. Schematic representation of the experimental workflow for the molecular characterization 
of circulating CTC isolated from blood sample of ACC patients. 
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To further assess the chromosomal alterations and the mutational state of ACC-
related genes in both tumor and CTC samples, we designed a target NGS assay, 
which included genes and Single Nucleotide Polymorphisms (SNPs) selected on the 
basis of the previous results on the larger European cohort of ACC patients. In 
particular, we selected 9 genes with a high percentage of mutation and prognostic 
value in ACC (ZNRF3, TP53, CTNNB1, CDKN2A, MEN1, RB1, CDK4  GNAS, 
PRKACA) and a selection of 173 SNPs related to 11 chromosome arms (1p, 1q, 2p, 
2q, 9q, 11p, 11q, 17q, 18p, 18q, 22q) previously identified as discriminating of 
chromosomal and noisy LOH profiles, or harboring the genes frequently found 
deleted in ACC. The SNP selection criteria included heterozygosity (average > 
0.4999) and  at least 100 kb distance one to the other in order to avoid the linkage 
disaequilibrium effect and to achieve as much coverage as possible for each 
chromosome arm. As for ddPCR, we first tested the new NGS panel on ACC tumor 
samples to compare the results to the previous analysis. We obtained encouraging 
preliminary results about  SNPs, confirming that the new NGS assay can replicate 
the previous SNP profiles in all the cases of chromosomal, quite or noisy LOH (Fig. 
Figure R20. ddPCR analysis assessing the presence of selected mutations in tumor and CTC-derived 
DNA. A specific ddPCR assay was designed for each of the selected mutations in ZNRF3 and TP53  
related to patient 2 (P2) and patient 13 (P13) of our cohort. The mutated and wild type alleles are 
detected thanks the complementary hybridization of a specific probe conjugated with a different 
fluorophore, FAM for the mutated (blue signal) and HEX for the wild allele (green signal). The grey 
signal represent the double-negative droplets. 
Results 
110 
R21). Further data analysis needs to be done to validate the NGS assay, including 
the evaluation of gene mutations.  
 
 
 
 
 
 
 
Figure R21. Representative images of  chromosomal (A), quiet (B) and noisy (C) LOH profiles related 
to tumor samples of three different ACC patients. The BAF (B Allele Frequency) plots refer to the 
previous NGS analysis; the mBAF (mirrored B Allele Frequency) plots are related to the analysis with 
the new targeted NGS panel. The chromosome arms harboring the analyzed SNPs are indicated on the 
mBAF plots and linked to the correspondent ones on the BAF plots by the red arrow. 
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Discussion 
The molecular and metabolic evolution within the primary tumor mass, together 
with a variety of stimuli produced in the surrounding microenvironment, underlies 
cancer cell ability to acquire metastatic traits and, eventually, disseminating through 
the blood circulation and colonizing distant organs. Since metastasis represents the 
main cause of death in cancer patients, preventing cancer cell spreading rather than 
treat secondary neoplasms would be more effective in high-risk patients. In this 
setting, the detection and characterization circulating tumor cells (CTCs) could serve 
as real-time "liquid biopsy" (Alix-Panabières & Pantel, 2013), allowing to profile the 
disease complexity at any stage of tumor progression. This would particularly 
helpful in the case of advanced adrenocortical carcinoma, aiding in developing 
more effective therapeutic strategies targeting specific traits of cells that retain the 
metastatic potential.  
CTC detection and count has been already shown to be a potential marker for 
differential diagnosis in ACC (Pinzani et al, 2013). Here, we aimed to develop an 
experimental design to characterize CTCs at the molecular level, in order to 
compare the genetic profile with that of the primary tumor and identify potential 
markers allowing for early detection of metastatic disease. 
CTC isolation by size, associated with the positivity for the adrenal specific 
marker SF-1,  remains the most useful tool in the case of ACC, since adrenocortical 
carcinoma have been shown to be EpCAM-negative (Went et al, 2004), thus making 
poorly efficient the EpCAM immunoselection-based systems for CTC detection. 
Using a dedicated filtration device, we were able to assess the presence of CTCs in 
blood samples from ACC patients under follow-up and with different 
characteristics of disease presentation. We were able not only to detecte single 
CTCs, but also CTC clusters (CTM), which have been associated with a more 
aggressive tumor behavior and poor clinical outcome (Hou et al, 2012; Aceto et al, 
2014, 2015; Au et al, 2016). Moreover, we also identified cancer-associated 
macrophages-like cells (CAML), which seems to be predictive of disease outcome in 
other cancer types (Adams et al,2014, 2016; Mu et al, 2017). The specific nuclear 
positivity for SF-1 in isolated cells confirmed the adrenal origin of the detected 
CTCs. However, some limitations are still present: first of all, our filtration system 
do not allow single CTC isolation, since a percenta
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on the filters. Employing more sensitive techniques for CTC isolation by size, 
followed by a specific selection for SF-1-positive cells, will help in overcoming this 
particular issue. 
Concerning CTC molecular characterization, we are still far from have enough 
amount of high quality DNA from CTCs suitable for downstream applications, such 
as digital-droplet PCR and next generation sequencing. However, our preliminary 
results with the designed assay addressing specific alterations in the primary 
tumors of ACC patients, are encouraging: in fact, we could confirm the presence of 
both point mutations and the specific LOH profiles in tumor samples of selected 
patients. Improving technical aspects related to DNA extraction, purification and 
amplification of CTC DNA will allow to pursue in this promising field, looking 
forward the application of "liquid biopsy" and CTCs for personalized therapy also 
in ACC. 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
Despite immunohistochemical and molecular studies have identified novel 
biomarkers of diagnostic and prognostic relevance for adrenocortical carcinoma, the 
discrimination between malignant and benign forms remains challenging, the 
molecular mechanism underlying the pathology has still to be fully elucidated and 
the available therapeutic options show limited specificity and efficacy. A better 
understanding of the tumor biology and behavior would help in identifying new 
therapeutic targets to develop a more personalized approach to treat patients. 
Beyond molecular alterations occurring within the tumor mass, including driver 
gene mutations, epigenetic alterations and dysregulation of signaling pathways 
related to cell survival, growth and proliferation, the role of the surrounding stroma 
has been widely recognized as crucial in sustaining tumor metabolic adaptation and 
evolution. Thus, unraveling the dynamics occurring in the setting of the ACC tumor 
microenvironment would help in elucidating the biology of adrenal tumorigenesis, 
shedding new light on the mechanisms driving cancer progression. Particularly, this 
would give a chance to address the metabolic and functional interactions potentially 
established between adrenocortical carcinoma cancer cells and their adipose 
microenvironment, allowing to uncouple such a crosstalk. Moreover, identifying 
more specific features of cells developing and retaining more aggressive traits could 
allow to monitor tumor progression, preventing tumor dissemination and 
metastasis. In this scenario, the "liquid biopsy" may represent the possibility to 
follow tumor evolution, with promising implications for the clinical practice. 
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